<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/264538-immunosuppressive-agent-and-anti-tumor-agent-comprising-heterocyclic-compound-as-active-ingredient by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:50:51 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 264538:IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>A novel immunosuppressive agent, more specifically an immunosuppressive agent comprising, as an active ingredient, a heterocyclic compound represented by the general formula (I) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof; a novel heterocyclic compound represented by the general formula (II) (wherein X or other variables are as defined in the specification) or a pharmaceutically acceptable salt thereof; and use of the compound or salt as an antitumor agent.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>SPECIFICATION<br>
IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING<br>
HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT<br>
TECHNICAL FIELD<br>
[0001] The present invention relates to novel immunosuppressive agents, and more<br>
specifically immunosuppressive agents comprising heterocyclic compounds of a specific<br>
structure as effective ingredients. The present invention also relates to novel chemical<br>
compounds among the above heterocyclic compounds, and further to the use of such<br>
novel compounds as antitumor agents.<br>
BACKGROUND ART<br>
[0002] In general, as disorders for which immunosuppressive agents may be used,<br>
mention may be made of a number of autoimmune diseases such as rejection after<br>
transplantation of organs or tissues, graft versus host disease after bone-marrow<br>
transplantation, inflammatory bowel diseases such as ulcerative colitis or Crohn disease,<br>
inflammatory or allergenic skin diseases such as psoriasis or atopic dermatitis,<br>
inflammatory or allergenic respiratory disorders such as chronic obstructive pulmonary<br>
disease or asthma, rheumatoid arthritis, systemic lupus erythematosus, scleroderma,<br>
Sjogren syndrome, or the like. In addition, immunosuppressive agents such as<br>
cyclophosphamide or methotrexate are employed also in the treatment of hematologic<br>
neoplasms such as multiple myeloma, malignant lymphoma, leukemia or the like.<br>
Furthermore, immunosuppressive agents may also be employed in combination with<br>
antibiotics in the case of the treatment of disorders characterized by an enhanced immune<br>
function associated with infection such as sepsis (Non-Patent Document 1).<br>
Thus, a number of immunosuppressive agents are presently utilized as therapeutic<br>
agents for the above-mentioned disorders in clinical practice. However, as it now stands,<br>
there still remain many problems to be improved due to a failure to obtain a sufficient<br>
therapeutic effect and an unexpected occurrence of side effects.<br>
[0003] A variety of cells such as T, B lymphocytes and factors are known to be involved<br>
in the inducement of the immune response. Since cyclosporin and tacrolimus, which are<br>
presently used for organ transplantation or the like, are restricted in their efficacy to T<br>
cells, there is a need for immunosuppressive agents which serve as agents for acting on<br>
1<br><br>
more extensive immune mechanisms, with less side effects in clinical applications, and<br>
acting simultaneously on a variety of cells involved in the disorders.<br>
Here, "a variety of cells involved in the disorders" are not limited to immune cells, i.e.,<br>
T cells, B cells, monocytes, macrophages, NK cells, NKT cells, dendritic cells, neutrophils,<br>
basophils, eosinophils, mast cells or the like. They should include cells in which functions<br>
are affected by humoral factors released from immune cells or membrane receptors on the<br>
immune cells. Examples of these cells include, but are not limited to platelets, vascular<br>
endothelial cells, synoviocytes, osteoclasts, osteoblasts, chondrocytes, tracheal epithelial<br>
cells, or the like. In addition, in the case where the humoral factors are autoantibodies,<br>
cells expressing target antigens are also included.<br>
[0004] Regarding benzimidazole ring-substituted s-triazine [1,3,5-triazine] derivatives and<br>
pyrimidine derivatives, the present inventors have studied their cytostatic activity on solid<br>
tumors, and have performed synthesis of a great number of such compounds as well as<br>
verification of the relationship between antitumor activity and chemical structure (see<br>
Patent Documents 1, 2, 3, 4 and 5).<br>
[0005] In particular, s-triazine derivatives and pyrimidine derivatives having a specific<br>
substituent at position 2 of the benzimidazole ring were found to exhibit an enhanced<br>
cytostatic activity on solid tumors (see Patent Documents 3, 4 and 5). The processes for<br>
the production of such derivatives are described in these patent documents, but are not<br>
limited to these, and various reactions such as alkylation, alkylcarbonylation or the like<br>
may be induced in the final products to employ the resultant as final compounds.<br>
Non-Patent Document 1: T. Munster et.al. Clin. Exp. Rheumatol., 17 (Suppl. 18): S29-S36<br>
(1999);<br>
Patent Document 1: WO 99/05138 pamphlet<br>
Patent Document 2: WO 00/43385 pamphlet<br>
Patent Document 3: WO 02/088112 pamphlet<br>
Patent Document 4: WO 2004/037812 pamphlet<br>
Patent Document 5: WO 2005/095389 pamphlet<br>
PROBLEMS TO BE SOLVED BY THE INVENTION<br>
[0006] The present inventors demonstrated that the above compounds specifically<br>
inhibited phosphatidylinositol 3-kinase (PI3K) activity (Non-Patent Document 2). PI3K is<br>
an enzyme that phosphorylates phosphatidylinositol (PI) on the cell membrane, classified<br>
into three subfamilies according to structures and its substrate specificity. Among these,<br>
2<br><br>
the compounds of the present invention specifically inhibit class I PI3K. Class I PI3K<br>
phosphorylates PI, phosphatidylinositol 4-phosphate, and phosphatidylinositol 4,5-<br>
biphosphate to produce phosphatidylinositol 3-phosphate, phosphatidylinositol 3,4-<br>
biphosphate, and phosphatidylinositol 3,4,5-triphosphate, respectively.<br>
Phosphatidylinositol 3,4,5-triphosphate thus produced serves as an intracellular second<br>
messenger. Class I PI3K is expressed in various cells, and exhibits a wide spectrum of<br>
functions such as cell proliferation, cell survival, glucose transport, cytoskeleton<br>
regulation and the like. In PI3K gene-knockout animals, development of B cells, T cells<br>
or the like and signal transduction are obstructed. Furthermore, the degranulation of mast<br>
cells and migration of leukocytes are also obstructed (Non-Patent Document 3).<br>
[0007] It is known that B cell proliferation by lipopolysaccharides (LPS) or anti-IgM<br>
antibodies is inhibited by wortmannin or LY294002, PI3K inhibitors (Non-Patent<br>
Document 4). Furthermore, wortmannin inhibits T cell proliferation induced by anti-CD3<br>
antibodies and anti-CD28 antibodies (Non-Patent Document 5).<br>
[0008] Hematologic neoplasms are characterized by a spontaneous enhancement of cell<br>
division and an inhibition of apoptosis of the immune cells. However, abnormalities of<br>
PI3K cascades such as reduction of PTEN proteins that dephosphorylate<br>
phosphatidylinositol 3,4,5-triphosphate and enhancement of Akt phosphorylation have<br>
been reported (Non-Patent Document 6). Furthermore, it was demonstrated that the<br>
inhibition of PI3K may result in the inhibition of the cell division and the induction of<br>
apoptosis of various hematologic neoplasms (e.g., Non-Patent Document 7).<br>
[0009] Rheumatoid arthritis is a disorder characterized by immune abnormalities and<br>
hypertrophy of synovial tissues. It is known that the hypertrophy of synovial tissues<br>
results from proliferation and inhibition of apoptosis of synoviocytes. In inflamed<br>
synovial tissues of patients with rheumatoid arthritis, the levels of phosphorylated Akt<br>
were increased due to the activation of PI3K (Non-Patent Document 8). Moreover, it was<br>
revealed that proliferation and inhibition of apoptosis of synoviocytes were normalized by<br>
the inhibition of PI3K in vitro study (Non-Patent Document 9).<br>
[0010] However, wortmannin and LY294002 have not been put to clinical use due to their<br>
toxicity. Furthermore, although a lot of candidates that have therapeutic potential for a<br>
wide spectrum of disorders such as inflammations, cancers and others have been<br>
developed to take advantage of PI3K's inhibitory property, none has been put to clinical<br>
use. Thus, there is a need for immunosuppressive agents which normalize the<br>
3<br><br>
hyperfunctioning of PI3K in various cells involved in disorder of immune system without<br>
exhibiting any toxicity to living subjects.<br>
Non-Patent Document 2: S. Yaguchi et al., 96th Annual Meeting of the AACR,<br>
Anaheim, CA, USA. April 16-20,2005, #1691.<br>
Non-Patent Document 3: R. Wetzker and C. Rommel, Current Pharmaceutical Design,<br>
2004, 10, 1915-1922<br>
Non-Patent Document 4: A. C. Donahue and D. A. Fruman, J. Immunol. 2003, 170, 5851-<br>
5860<br>
Non-Patent Document 5: S. G. Ward et al., Eur J Immunol. 1995, 25, 526-532<br>
Non-Patent Document 6: P. Workmann, Biochem. Soc. Trans. 2004, 32, 393-396<br>
Non-Patent Document 7: S. Uddin et al., Biochem. Biophys. Res. Commun. 2004, 320,<br>
932-938<br>
Non-Patent Document 8: H. Zhang et al., Arthritis Rheum 2001, 44,1555-1567<br>
Non-Patent Document 9: T. Miyashita et al., Biochem Biophys Res Commun 2003, 312,<br>
397-404<br>
MEANS TO SOLVE THE PROBLEMS<br>
[0011] In view of the foregoing, the present inventors have conducted extensive research<br>
on the heterocyclic compounds disclosed in Patent Documents 1, 2, 3, 4 and 5 on the<br>
assumption that some might be useful for the disorders for which immunosuppressive<br>
agents are used, such as for autoimmune diseases, organ transplantation, allergic diseases,<br>
hematologic neoplasm, sepsis or the like. As a result, they found that the heterocyclic<br>
compounds represented by the following general formula (I) are effective, arriving at<br>
completion of the present invention.<br>
[0012] Thus, one aspect of the present invention provides an immunosuppressive agent<br>
comprising as an effective ingredient a heterocyclic compound represented by the general<br>
Formula (I):<br>
4<br><br><br>
wherein,<br>
X represents a nitrogen atom or CH;<br>
both or either of R1 and R2 represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difluoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
R6 represents a morpholino (optionally substituted with one or two C1-C6 alkyl groups), a<br>
pyrrolidinyl (optionally substituted with a hydroxy C1-C6 alkyl), a piperidino (which is<br>
optionally substituted with one or two oxygen atoms, a hydroxyl group, a formyl, or a C1-<br>
C6 alkyl), a piperazinyl (optionally substituted with one or two oxygen atoms, the nitrogen<br>
at position 4 being optionally substituted with a substituent selected from the group<br>
consisting of a formyl, a C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl,<br>
an aromatic carbonyl, a benzylcarbonyl, and a substituted carbamoyl), or a 1,4-diazepano<br>
(optionally substituted with one or two oxygen atoms, the nitrogen at position 4 being<br>
optionally substituted with a substituent selected from the group consisting of a formyl, a<br>
C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a<br>
benzylcarbonyl, and a substituted carbamoyl);<br>
or a pharmaceutically acceptable salt thereof.<br>
[0013] Here, one embodiment provides an immunosuppressive agent wherein in Formula<br>
(I), either of R1 or R2 is a hydroxyl group. Another embodiment provides an<br>
immunosuppressive agent wherein in Formula (I), either of R1 or R2 is a hydroxyl group,<br>
and R3 is a difluoromethyl. A further embodiment provides an immunosuppressive agent<br>
wherein in Formula (I), both of R1 and R2 are hydrogens, and R3 is a difluoromethyl. A<br>
further embodiment provides an immunosuppressive agent wherein in Formula (I), R6 is a<br>
4-acetylpiperazine.<br>
5<br><br>
[0014] In the foregoing, the disorders to be treated may be rejection and graft versus host<br>
diseases, inflammatory bowel diseases such as ulcerative colitis or Crohn disease,<br>
inflammatory or allergenic skin diseases such as psoriasis or atopic dermatitis;<br>
inflammatory or allergenic respiratory disorders such as obstructive pulmonary diseases or<br>
asthma; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus,<br>
scleroderma or Sjogren syndrome; hematological neoplasms such as malignant lymphoma,<br>
multiple myeloma, chronic leukemia, acute leukemia, or myelocytic leukemia; sepsis,<br>
fulminant hepatitis and the like.<br>
[0015] Here, one embodiment provides a PI3K inhibitor wherein in Formula (I), either of<br>
R1 or R2 is a hydroxyl group. Another embodiment provides a PI3K inhibitor wherein in<br>
Formula (I), either of R1 or R2 is a hydroxyl group, and R3 is a difluoromethyl. A further<br>
embodiment provides a PI3K inhibitor wherein in Formula (I), both of R1 and R2 are<br>
hydrogens, and R3 is a difluoromethyl. Furthermore, a PI3K inhibitor wherein in Formula<br>
(I), R6 is a 4-acetylpiperazine is provided.<br>
[0016] In the foregoing, the disorders to be treated may be rejection and graft versus host<br>
diseases, inflammatory bowel diseases such as ulcerative colitis or Crohn disease,<br>
inflammatory or allergenic skin diseases such as psoriasis or atopic dermatitis;<br>
inflammatory or allergenic respiratory disorders such as obstructive pulmonary diseases or<br>
asthma; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus,<br>
scleroderma or Sjogren syndrome; hematological neoplasms such as malignant lymphoma,<br>
multiple myeloma, chronic leukemia, or acute leukemia; sepsis, fulminant hepatitis and<br>
the like.<br>
[0017] Among the heterocyclic compounds of Formula (I) which are used in the<br>
immunosuppressive agents in accordance with the present invention, some compounds are<br>
novel in their structures. Thus, in another aspect, the present invention provides a<br>
heterocyclic compound represented by the general Formula (II):<br><br>
wherein,<br>
6<br><br>
n represents 0-2;<br>
X represents a nitrogen atom or CH;<br>
Y represents -(CH2)n1-, wherein n1 is 1-2;<br>
R1 and R2, both or either, represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difluoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
R7 represents a hydrogen atom, a C1-C6 alkyl group, a formyl, a C1-C6 hydroxyalkyl, a C1-<br>
C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a benzylcarbonyl, or a<br>
substituted carbamoyl;<br>
or a pharmaceutically acceptable salt thereof.<br>
[0018] Here, in the above Formula (II), R7 may represent a hydrogen atom or a C1-C6<br>
alkyl group; R6 may represent a hydrogen atom or a C1-C6 alkyl group. Examples include:<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-morpholino-1,3,5-<br>
triazine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(cis-2,3-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)-1,3,5 -triazine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(2,2-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
4-(4-acetylpiperazin-1-yl)-2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-6-<br>
morpholino-1,3,5-triazine;<br>
4-(4-acetylpiperazin-l-yl)-2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-6-morpholino-<br>
1,3,5-triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-hydroxymethylbenzimidazol-1 -yl)-6-morpholino-1,3,5-<br>
triazine;<br>
4-(4-acetylpiperazin-1-yl)-2-(2-difluoromethylbenzimidazol-1-yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(cis-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
7<br><br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-hydroxymethylbenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
(cis-2,3-dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
(trans-2,3-dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-1 -yl]-6-<br>
(2,2-dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoyl-<br>
piperazin)-1 -yl] -6-morpholino-1,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-<br>
l-yl]-6-morpholino-l,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
morpholino-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
(cis-2,3-dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
(trans-2,3-dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
(2,2-dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoyl-<br>
piperazin)-1 -yl] -6-morpholinopyrimidine;<br>
8<br><br>
2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-<br>
1-yl]-6-morpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-1 -yl]-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-morpholino-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-(cis-2,3-<br>
dimethylmorpholino-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-(trans-2,3-<br>
dimethylmorpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(2-furoyl)piperazin-1 -yl] -6-(2,2-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-<br>
morpholino-l,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-<br>
morpholino-1,3,5-triazine;<br>
4-[4-(2-furoyl)piperazin-1 -yl]-2-(2-hydroxymethylbenzimidazol-1 -yl)-6-morpholino-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-(cis-2,3-<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(2-furoyl)piperazin-1 -yl] -6-(trans-2,3 -<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-[4-(2-furoyl)piperazin-1 -yl]-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4- [4-(2-furoyl)piperazin-1 -yl] -6-<br>
morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-<br>
morpholinopyrimidine;<br>
4-[4-(2-furoyl)piperazin-l-yl]-2-(2-hydroxymethylbenzimidazol-l-yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-morpholino-1,3,5-<br>
triazine;<br>
9<br><br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(cis-2,3-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(2,2-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
4-(4-acetonylpiperazin-1-yl)-2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-6-<br>
morpholino-1,3,5-triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-6-<br>
morpholino-1,3,5 -triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-hydroxymethylbenzimidazol-l-yl)-6-morpholino-l,3,5-<br>
triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(cis-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetonylpiperazin-1-yl)-2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-1-yl)-2-(2-hydroxymethylbenzimidazol-1-yl)-6-<br>
morpholinopyrimidinn;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -yl)-1,3,5-<br>
triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(cis-2,3-dimethylmorpholino-6-(4-<br>
propionylpiperazin-1 -yl)-l ,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(trans-2,3-dimethylmorpholino-6-(4-<br>
propionylpiperazin-l-yl)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethylmorpholino-6-(4-<br>
propionylpiperazin-1 -yl)-1,3,5-triazine;<br>
10<br><br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-morpholino-6-(4-propionylpiperazin-<br>
l-yl)-l,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)-l,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -yl)-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(cis-2,3-dimethylmorpholino-6-(4-<br>
propionylpiperazin-1 -yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(trans-2,3-dimethylmorpholino-6-(4-<br>
propionylpiperazin-1 -yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethylmorpholino-6-(4-<br>
propionylpiperazin-1 -yl)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-morpholino-6-(4-propionylpiperazin-<br>
l-yl)pyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)pyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazin-1 -yl)-6-morpholino-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-(cis-2,3 -<br>
dimethylmorpholino)-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-(trans-2,3 -<br>
dimethylmorpholino)-1,3,5 -triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-(2,2-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholino-l,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-morpholino-<br>
1,3,5-triazine;<br>
11<br><br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxyacetylpiperazi-l-yl)-6-(cis-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxyacetylpiperazi-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(3-hydroxypropyl)piperazi-l-yl]-6-(cis-2,3-<br>
dimethylmorpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-(trans-2,3-<br>
dimethylmorpholino-1,3,5 -triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(3-hydroxypropyl)piperazi-l-yl]-6-(2,2-<br>
dimethylmorpholino-1,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -<br>
6-morpholino-l ,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-4-[4-(3-hydroxypropyl)piperazi-l-yl]-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-[4-(3-hydroxypropyl)piperazi-1 -yl]-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(3-hydroxypropyl)piperazi-l-yl]-6-(cis-2,3-<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-(trans-2,3 -<br>
dimethylmorpholinopyrimidine;<br>
12<br><br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(3-hydroxypropyl)piperazi-l-yl]-6-(2,2-<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -<br>
6-morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1-yl)-4-(4-methoxycarbonylpiperazin-1-yl)-6-(cis-2,3 -<br>
dimethylmorpholino)-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-(trans-<br>
2,3-dimethylmorpholino)-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1-yl)-4-(4-methoxycarbonylpiperazin-1-yl)-6-(2,2-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-<br>
6-morpholino-1,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholino-l,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-(cis-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-(trans-<br>
2,3-dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-<br>
6-morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholinopyrimidine;<br>
13<br><br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-morpholino-6-(5-oxo-l,4-diazepan-l-yl)-l,3,5-<br>
triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-morpholino-6-(3-oxopiperazin-l-yl)-l,3,5-<br>
triazine; and<br>
2-(2-difluoromethylbenzimidazol-l-yl)-6-(3,5-dioxopiperazin-l-yl)-4-morpholino-l,3,5-<br>
triazine.<br>
[0019] Furthermore, the present inventors have found novel uses as antitumor agents for<br>
the novel compounds represented by the above Formula (II). Thus, a further embodiment<br>
relates to an antitumor agent comprising a compound of Formula (II) as an effective<br>
ingredient. The disorders of interest may include, but are not limited to, lung cancer,<br>
prostate cancer, breast cancer, colon cancer, gastric cancer, pancreatic cancer, liver cancer,<br>
esophageal cancer, brain tumor, ovarian cancer, uterine cancer, malignant melanoma, renal<br>
cancer, head and neck cancer, skin cancer, bladder cancer, osteogenic sarcoma, biliary<br>
tract cancer, vulvar cancer, testicular neoplasm, penile cancer, colorectal cancer,<br>
mediastinal neoplasm, urothelial carcinoma, choriocarcinoma, soft tissue sarcoma, thyroid<br>
cancer, parathyroid cancer, adrenal cancer, malignant pheochromocytoma, germ cell<br>
tumor and the like.<br>
[0020] Furthermore, the present invention relates to the following various embodiments.<br>
The present invention relates to a method for immunosuppression comprising<br>
administering to a mammal a therapeutically effective amount of a heterocyclic compound<br>
represented by the general Formula (I):<br><br>
wherein,<br>
X represents a nitrogen atom or CH;<br>
14<br><br>
both or either of R1 and R2 represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difiuoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
R6 represents a morpholino (optionally substituted with one or two C1-C6 alkyl groups), a<br>
pyrrolidinyl (optionally substituted with a hydroxy C1-C6 alkyl), a piperidino (which is<br>
optionally substituted with one or two oxygen atoms, a hydroxyl group, a formyl, or a C1-<br>
C6 alkyl), a piperazinyl (optionally substituted with one or two oxygen atoms, the nitrogen<br>
at position 4 being optionally substituted with a substituent selected from the group<br>
consisting of a formyl, a C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl,<br>
an aromatic carbonyl, a benzylcarbonyl, and a substituted carbamoyl), or a 1,4-diazepano<br>
(optionally substituted with one or two oxygen atoms, the nitrogen at position 4 being<br>
optionally substituted with a substituent selected from the group consisting of a formyl, a<br>
C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a<br>
benzylcarbonyl, and a substituted carbamoyl);<br>
or a pharmaceutically acceptable salt thereof.<br>
Here, in one embodiment, in Formula (I), either of R1 or R2 is hydroxyl group. In<br>
another embodiment, in Formula (I), either of R1 or R2 is hydroxyl group, and R3 is<br>
difiuoromethyl. In a further embodiment, in Formula (I), both of R1 and R2 are hydrogens,<br>
and R3 is difiuoromethyl. In a further embodiment, in Formula (I), R6 is 4-<br>
acetylpiperazine.<br>
Furthermore, as the disorders to be treated, mention can be made of rejection and<br>
graft versus host disease; inflammatory bowel diseases such as ulcerative colitis or Crohn<br>
disease; inflammatory or allergenic skin diseases such as psoriasis or atopic dermatitis;<br>
inflammatory or allergenic respiratory disorders such as obstructive pulmonary diseases or<br>
asthma; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus,<br>
scleroderma, Sjogren syndrome, or the like; hematologic neoplasms such as malignant<br>
lymphoma, multiple myeloma, chronic leukemia, acute leukemia or the like; sepsis,<br>
fulminant hepatitis and the like.<br>
[0021] Yet another embodiment relates to a method for treating tumors comprising<br>
administering to a patient a therapeutically effective amount of a heterocyclic compound<br>
represented by the general Formula (II):<br>
15<br><br><br>
wherein,<br>
n represents 0-2;<br>
X represents a nitrogen atom or CH;<br>
Y	represents -(CH2)n1-, wherein n1 is 1-2;<br>
R1 and R2, both or either, represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difluoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
R7 represents a hydrogen atom, a C1-C6 alkyl group, a formyl, a C1-C6 hydroxyalkyl, a C1-<br>
C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a benzylcarbonyl, or a<br>
substituted carbamoyl;<br>
or a pharmaceutically acceptable salt thereof.<br>
[0022] In yet another embodiment, the present invention relates to an immunosuppressive<br>
composition comprising a therapeutically effective amount of a heterocyclic compound<br>
represented by the general Formula (II):<br><br>
wherein,<br>
n represents 0-2;<br>
X represents a nitrogen atom or CH;<br>
Y	represents -(CH2)n1-, wherein n1 is 1-2;<br>
16<br><br>
R1 and R2, both or either, represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difluoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
R7 represents a hydrogen atom, a C1-C6 alkyl group, a formyl, a C1-C6 hydroxyalkyl, a C1-<br>
C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a benzylcarbonyl, or a<br>
substituted carbamoyl; or a pharmaceutically acceptable salt thereof and a<br>
pharmaceutically acceptable carrier. In a yet further embodiment, the invention relates to<br>
a composition, in particular a pharmaceutical composition, and more preferably an<br>
antitumor composition, comprising a therapeutically effective amount of a heterocyclic<br>
compound represented by the general Formula (II) or a pharmaceutically acceptable salt<br>
thereof and a pharmaceutically acceptable carrier.<br>
[0023] Furthermore, the present invention relates to the following various embodiments.<br>
The present invention relates to a PI3K inhibition method comprising administering to a<br>
mammal a therapeutically effective amount of a heterocyclic compound represented by the<br>
general Formula (I):<br><br>
wherein,<br>
X represents a nitrogen atom or CH;<br>
both or either of R1 and R2 represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difluoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
17<br><br>
R6 represents a morpholino (optionally substituted with one or two C1-C6 alkyl groups), a<br>
pyrrolidinyl (optionally substituted with a hydroxy C1-C6 alkyl), a piperidino (which is<br>
optionally substituted with one or two oxygen atoms, a hydroxyl group, a formyl, or a C1-<br>
C6 alkyl), a piperazinyl (optionally substituted with one or two oxygen atoms, the nitrogen<br>
at position 4 being optionally substituted with a substituent selected from the group<br>
consisting of a formyl, a C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl,<br>
an aromatic carbonyl, a benzylcarbonyl, and a substituted carbamoyl), or a 1,4-diazepano<br>
(optionally substituted with one or two oxygen atoms, the nitrogen at position 4 being<br>
optionally substituted with a substituent selected from the group consisting of a formyl, a<br>
C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a<br>
benzylcarbonyl, and a substituted carbamoyl);<br>
or a pharmaceutically acceptable salt thereof.<br>
Here, in one embodiment, in Formula (I), either of R1 or R2 is hydroxyl group. In<br>
another embodiment, in Formula (I), either of R1 or R2 is hydroxyl group, and R3 is<br>
difiuoromethyl. In a further embodiment, in Formula (I), both of R1 and R2 are hydrogens,<br>
and R3 is difiuoromethyl. In a further embodiment, in Formula (I), R6 is 4-<br>
acety lpiperazine.<br>
Furthermore, as the disorders to be treated, mention can be made of rejection and<br>
graft versus host disease; inflammatory bowel diseases such as ulcerative colitis or Crohn<br>
disease; inflammatory or allergenic skin diseases such as psoriasis or atopic dermatitis;<br>
inflammatory or allergenic respiratory disorders such as obstructive pulmonary diseases or<br>
asthma; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus,<br>
scleroderma, Sjagren syndrome, or the like; hematologic neoplasms such as malignant<br>
lymphoma, multiple myeloma, chronic leukemia, acute leukemia or the like; sepsis,<br>
fulminant hepatitis and the like.<br>
[0024] In yet another embodiment, the present invention relates to a PI3K inhibitory<br>
composition comprising a therapeutically effective amount of a heterocyclic compound<br>
represented by Formula (I):<br>
18<br><br><br>
wherein,<br>
X represents a nitrogen atom or CH;<br>
both or either of R1 and R2 represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difluoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
R6 represents a morpholino (optionally substituted with one or two C1-C6 alkyl groups), a<br>
pyrrolidinyl (optionally substituted with a hydroxy C1-C6 alkyl), a piperidino (which is<br>
optionally substituted with one or two oxygen atoms, a hydroxyl group, a formyl, or a C1-<br>
C6 alkyl), a piperazinyl (optionally substituted with one or two oxygen atoms, the nitrogen<br>
at position 4 being optionally substituted with a substituent selected from the group<br>
consisting of a formyl, a C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl,<br>
an aromatic carbonyl, a benzylcarbonyl, and a substituted carbamoyl), or a 1,4-diazepano<br>
(optionally substituted with one or two oxygen atoms, the nitrogen at position 4 being<br>
optionally substituted with a substituent selected from the group consisting of a formyl, a<br>
C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a<br>
benzylcarbonyl, and a substituted carbamoyl);<br>
or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. In<br>
a yet further embodiment, the invention relates to a composition, in particular a<br>
pharmaceutical composition, and more preferably a PI3K inhibitory composition,<br>
comprising a therapeutically effective amount of a heterocyclic compound represented by<br>
the general Formula (II) or a pharmaceutically acceptable salt thereof and a<br>
pharmaceutically acceptable carrier.<br>
[0025] Furthermore, the present invention relates to use of a heterocyclic compound<br>
represented by Formula (I):<br>
19<br><br><br>
wherein,<br>
X represents a nitrogen atom or CH;<br>
both or either of R1 and R2 represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difiuoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
R6 represents a morpholino (optionally substituted with one or two C1-C6 alkyl groups), a<br>
pyrrolidinyl (optionally substituted with a hydroxy C1-C6 alkyl), a piperidino (which is<br>
optionally substituted with one or two oxygen atoms, a hydroxyl group, a formyl, or a C1-<br>
C6 alkyl), a piperazinyl (optionally substituted with one or two oxygen atoms, the nitrogen<br>
at position 4 being optionally substituted with a substituent selected from the group<br>
consisting of a formyl, a C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl,<br>
an aromatic carbonyl, a benzylcarbonyl, and a substituted carbamoyl), or a 1,4-diazepano<br>
(optionally substituted with one or two oxygen atoms, the nitrogen at position 4 being<br>
optionally substituted with a substituent selected from the group consisting of a formyl, a<br>
C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a<br>
benzylcarbonyl, and a substituted carbamoyl);<br>
or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the<br>
treatment of immune diseases, or as an immunosuppressive agent.<br>
Here, in one embodiment, in Formula (I), either of R1 or R2 is hydroxyl group. In<br>
another embodiment, in Formula (I), either of R1 or R2 is hydroxyl group, and R3 is<br>
difiuoromethyl. In a further embodiment, in Formula (I), both of R1 and R2 are hydrogens,<br>
and R3 is difiuoromethyl. In a further embodiment, in Formula (I), R6 is a 4-<br>
acetylpiperazine.<br>
20<br><br>
Furthermore, as the disorders to be treated, mention can be made of rejection and<br>
graft versus host disease; inflammatory bowel diseases such as ulcerative colitis or Crohn<br>
disease; inflammatory or allergenic skin diseases such as psoriasis or atopic dermatitis;<br>
inflammatory or allergenic respiratory disorders such as obstructive pulmonary diseases or<br>
asthma; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus,<br>
scleroderma, Sjogren syndrome, or the like; hematologic neoplasms such as malignant<br>
lymphoma, multiple myeloma, chronic leukemia, acute leukemia or the like; sepsis,<br>
fulminant hepatitis and the like.<br>
[0026] In yet another embodiment, the present invention relates to use of a heterocyclic<br>
compound represented by the general Formula (II):<br>
wherein, <br>
n represents 0-2;<br>
X represents a nitrogen atom or CH;<br>
Y represents -(CH2)n1-, wherein n1 is 1-2;<br>
R1 and R2, both or either, represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difluoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
R7 represents a hydrogen atom, a C1-C6 alkyl group, a formyl, a C1-C6 hydroxyalkyl, a C1-<br>
C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a benzylcarbonyl, or a<br>
substituted carbamoyl;<br>
or a pharmaceutically acceptable salt thereof in the manufacture of a composition for<br>
threatment of tumors.<br>
In yet another embodiment, the present invention relates to use of a heterocyclic<br>
compound represented by Formula (I):<br>
21<br><br><br>
wherein,<br>
X represents a nitrogen atom or CH;<br>
both or either of R1 and R2 represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difluoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
R6 represents a morpholino (optionally substituted with one or two C1-C6 alkyl groups), a<br>
pyrrolidinyl (optionally substituted with a hydroxy C1-C6 alkyl), a piperidino (which is<br>
optionally substituted with one or two oxygen atoms, a hydroxyl group, a formyl, or a C1-<br>
C6 alkyl), a piperazinyl (optionally substituted with one or two oxygen atoms, the nitrogen<br>
at position 4 being optionally substituted with a substituent selected from the group<br>
consisting of a formyl, a C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl,<br>
an aromatic carbonyl, a benzylcarbonyl, and a substituted carbamoyl), or a 1,4-diazepano<br>
(optionally substituted with one or two oxygen atoms, the nitrogen at position 4 being<br>
optionally substituted with a substituent selected from the group consisting of a formyl, a<br>
C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a<br>
benzylcarbonyl, and a substituted carbamoyl);<br>
or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the<br>
inhibition of PI3K or as a PI3K inhibition agent.<br>
Here, in one embodiment, in Formula (I), either of R1 or R2 is hydroxyl group. In<br>
another embodiment, in Formula (I), either of R1 or R2 is hydroxyl group, and R3 is<br>
difluoromethyl. In a further embodiment, in Formula (I), both of R1 and R2 are hydrogens,<br>
and R3 is difluoromethyl. In a further embodiment, in Formula (I), R6 is a 4-<br>
acetylpiperazine.<br>
22<br><br>
Furthermore, as the disorders to be treated, mention can be made of rejection and<br>
graft versus host disease; inflammatory bowel diseases such as ulcerative colitis or Crohn<br>
disease; inflammatory or allergenic skin diseases such as psoriasis or atopic dermatitis;<br>
inflammatory or allergenic respiratory disorders such as obstructive pulmonary diseases or<br>
asthma; autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus,<br>
scleroderma, Sjogren syndrome, or the like; hematologic neoplasms such as malignant<br>
lymphoma, multiple myeloma, chronic leukemia, acute leukemia or the like; sepsis,<br>
fulminant hepatitis and the like.<br>
Yet other embodiments, modes and features of the present invention will be<br>
apparent to those skilled in the art in view of the detailed description below.<br>
EFFECT OF THE INVENTION<br>
[0027] The agents of the invention are effective for the prevention or treatment of the<br>
disorders attributable to the hyperfunctioning of PI3K such as autoimmne diseases, organ<br>
transplantation, allergenic or inflammatory disorders, hematologic neoplasms, sepsis, and<br>
treatment of tumors.<br>
BRIEF EXPLANATION OF THE DRAWINGS<br>
[0028] [Figure 1] Diagrams showing the effects of test substances on the upregulation<br>
of CD 69 expression and CD 40L expression on human peripheral blood mononuclear<br>
cells induced by anti-human CD3 antibody and anti-human CD28 antibody.<br>
[Figure 2] Graph depicting a comparison between test substance-treated group and<br>
control group on the volume change in hind paw of rats after the onset of arthritis.<br>
[Figure 3] Graph depicting a comparison between test substance-treated group and<br>
control group on the change in arthritis score after the onset of arthritis.<br>
[Figure 4] Graph depicting a comparison between test substance-treated group and<br>
control group in a human B lymphoma xenografted model.<br>
BEST MODES FOR CARRYING OUT THE PRESENT INVENTION<br>
[0029] The heterocyclic compound for use in the present invention is the one represented<br>
by the general Formula (I):<br>
23<br><br><br>
wherein,<br>
X represents a nitrogen atom or CH;<br>
both or either of R1 and R2 represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difluoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
R6 represents a morpholino (optionally substituted with one or two C1-C6 alkyl groups), a<br>
pyrrolidinyl (optionally substituted with a hydroxy C1-C6 alkyl), a piperidino (which is<br>
optionally substituted with one or two oxygen atoms, a hydroxyl group, a formyl, or a C1-<br>
C6 alkyl), a piperazinyl (optionally substituted with one or two oxygen atoms, the nitrogen<br>
at position 4 being optionally substituted with a substituent selected from the group<br>
consisting of a formyl, a C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl,<br>
an aromatic carbonyl, a benzylcarbonyl, and a substituted carbamoyl), or a 1,4-diazepano<br>
(optionally substituted with one or two oxygen atoms, the nitrogen at position 4 being<br>
optionally substituted with a substituent selected from the group consisting of a formyl, a<br>
C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a<br>
benzylcarbonyl, and a substituted carbamoyl);<br>
or its pharmaceutically acceptable salt.<br>
[0030] In the above formula, "C1-C6" without any limitation means a group having 1 to 6<br>
carbon atoms. "C1-C6 alkyl" includes alkyl groups of linear or branched chain, such as<br>
methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, n-pentyl, n-hexyl and the like. "C1-<br>
C6 alkoxy" includes alkoxy groups with linear or branched chain, such as methoxy,<br>
ethoxy, n-propoxy, isopropoxy, n-butoxy, tert-butoxy, seobutoxy, n-pentyloxy, n-<br>
hexyloxy and the like. "Hydroxy C1-C6 alkyl" means those groups having a hydroxyl<br>
group bonded to any of the carbon atoms of the group defined by the above "C1-C6 alkyl".<br>
24<br><br>
When the above heterocyclic compound has an asymmetric carbon atom in its<br>
structure, isomers from the asymmetric carbon atom and their mixture (racemic<br>
compounds) exist, and any such compounds are to be included among the compounds of<br>
the present invention.<br>
[0031] Furthermore, the heterocyclic compounds that are used as effective ingredients of<br>
the present invention may be in the form of an acid addition salt as a pharmaceutically<br>
acceptable salt. Appropriate acid addition salts include inorganic acid salts such as<br>
hydrochlorides, sulfates, hydrobromides, nitrates, phosphates or the like, and organic acid<br>
salts such as acetates, oxalates, propionates, glycollates, lactates, pyruvates, malonates,<br>
succinates, maleates, fumarates, malates, tartrates, citrates, benzoates, cinnamates,<br>
methane sulfonates, benzene sulfonates, p-toluene sulfonates, salicylates or the like.<br>
[0032] The compounds which can be used as the effective ingredients of the present<br>
invention include, but are not limited to, the following heterocyclic compounds:<br>
[0033] 2-(2-Methylbenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine (Compound 1)<br>
[0034] 2-(Benzimidazol-l-yl)-4-(trans-2,3-dimethylmorpholino)-6-morpholino-l,3,5-<br>
triazine (Compound 2)<br>
[0035] 4,6-Dimorpholino-2-(2-hydroxymethylbenzimidazol-l-yl)-l,3,5-triazine<br>
(Compound 3)<br>
[0036] 2-(2-Difluoromethylbenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 4)<br>
[0037] 2-(2-Aminobenzimidazol-l-yl)-4,6-dimorpholinopyrimidine (Compound 5)<br>
[0038] 2-(2-Aminobenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine (Compound 6)<br>
[0039] 2-(2-Difluoromethylbenzimidazol-l-yl)-4-piperidino-6-morpholino-l,3,5-triazine<br>
(Compound 7)<br>
[0040] 2-(6-Amino-2-difluoromethylbenzimidazol-l-yl)-4-(cis-2,3-dimethylmorpholino)-<br>
6-morpholino-l,3,5-triazine (Compound 8)<br>
[0041] 2-(2-Difluoromethyl-6-ethoxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 9)<br>
[0042] 2-(2-Difluoromethyl-4-methylbenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 10)<br>
[0043] 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-morpholino-6-(2,6-<br>
dimethylmorpholino)pyrimidine (Compound 11)<br>
[0044] 2-(2-Difluoromethyl-5-hydroxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 12)<br>
25<br><br>
[0045] 2-(6-Amino-2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholino-l,3,5-triazine (Compound 13)<br>
[0046] 2-(4-Amino-2-difluoromethylbenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 14)<br>
[0047] 2-(2-Difluoromethyl-4-hydroxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 15)<br>
[0048] 2-(2-Difluoromethyl-6-hydroxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 16)<br>
[0049] 2-(5-Amino-2-difluoromethylbenzimidazol-1-yl)-4,6-di(2,6-dimethyl-<br>
morpholino)pyrimidine (Compound 17)<br>
[0050] 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4,6-dimorpholinopyrimidine<br>
(Compound 18)<br>
[0051] 2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethyl-<br>
morpholino)-6-morpholino-l,3,5-triazine (Compound 19)<br>
[0052] 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(2-hydroxymethyl-<br>
pyrrolidin-l-yl)-6-morpholino-l,3,5-triazine (Compound 20)<br>
[0053] 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholinopyrimidine (Compound 21)<br>
[0054] 2-(2-Difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(3,3-dimethylmorpholino)-6-<br>
morpholinopyrimidine (Compound 22)<br>
[0055] 2-(2-Difluoromethyl-5-methoxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-<br>
triazine (Compound 23)<br>
[0056] 2-(2-Difluoromethyl-4-methoxybenzimidazol-l-yl)-4-(cis-2,6-dimethyl-<br>
morpholino)-6-morpholinopyrimidine (Compound 24)<br>
[0057] 2-(2-Difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(5-oxo-1,4-diazepan-1 -<br>
yl)-l,3,5-triazine (Compound 25)<br>
[0058] 2-(2-Difluoromethylbenzimidazol-1 -yl)-4-(4-hydroxypiperizin-1 -yl)-6-<br>
morpholino-l,3,5-triazine (Compound 26)<br>
[0059] 2-(2-Difluoromethylbenzimidazol-l-yl)-4-[4-(2-hydroxyethyl)piperazin-l-yl]-6-<br>
morpholino-l,3,5-triazine (Compound 27)<br>
[0060] 4-(4-Acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-morpholino-<br>
1,3,5-triazine (Compound 28)<br>
[0061] 2-(2-Difluoromethylbenzimidazol-l-yl)-4-(4-benzylcarbonylpiperazin-l-yl)-6-<br>
morpholino-l,3,5-triazine (Compound 29)<br>
26<br><br>
[0062] 4-(4-Acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-<br>
morpholino-l,3,5-triazine (Compound 30)<br>
[0063] 2-(2-Difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-<br>
morpholino-l,3,5-triazine (Compound 31)<br>
[0064] 2-(2-Difluoromethylbenzimidazol-1 -yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-<br>
l-yl]-6-morpholino-l,3,5-triazine (Compound 32)<br>
[0065] 2-(2-Difluoromethylbenzimidazol-1 -yl)-4-(4-methoxylacetylpiperazin-1 -yl)-6-<br>
morpholino-l,3,5-triazine (Compound 33)<br>
[0066] 2-(2-Difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholino-l,3,5-triazine (Compound 34)<br>
[0067] 2-(2-Difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)-l,3,5-triazine (Compound 35)<br>
[0068] 2-(2-Difluoromethyl-4-methoxybenzimidazol-1 -yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholinopyrimidine (Compound 36)<br>
[0069] 2-(2-Difluoromethyl-4-methoxybenzimidazol-l-yl)-4-(cis-2,3-dimethyl-<br>
morpholino)-6-morpholinopyrimidine (Compound 37)<br>
[0070] 2-(2-Difluoromethyl-4-ethoxybenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholinopyrimidine (Compound 38)<br>
[0071] As will be demonstrated in Examples to be hereinafter described, the agents of the<br>
present invention inhibit the activation of T cells and B cells induced by Con A, LPS, anti-<br>
IgM antibody, anti-CD3 antibody + anti-CD28 antibody, thereby exhibiting PI3K<br>
inhibitory action on the immune cells. Thus, the drugs of the present invention can be<br>
used in the treatment and prevention of disorders of immune system attributable to the<br>
hyperfunctioning of PI3K.<br>
[0072] As disorders of immune system attributable to the hyperfunctioning of PI3K,<br>
mention may be made of: autoimmune diseases such as rheumatoid arthritis, systemic<br>
lupus erythematosus, scleroderma, Sjegren syndrome, or the like; organ dysfunction<br>
associated with autoimmune diseases such as uveitis, glomerulonephritis, thyroiditis,<br>
pancreatitis, bone destruction or the like; rejection after transplantation of tissues, graft<br>
versus host disease after bone-marrow transplantation; inflammatory bowel diseases such<br>
as ulcerative colitis or Crohn disease; inflammatory or allergenic skin diseases such as<br>
psoriasis or atopic dermatitis; inflammatory or allergenic respiratory disorders such as<br>
chronic obstructive pulmonary disease or asthma; allergenic conjunctivitis or rhinitis;<br>
hematologic neoplasm originated from immune cells, such as B-cell lymphoma, T-cell<br>
27<br><br>
lymphoma, myeloid leukemia or the like; sepsis triggered by infection with gram-negative<br>
bacteria or coronavirus, severe acute respiratory syndrome, fulminant hepatitis or the like.<br>
[0073] While the agents of the present invention can be applied to mammals such as<br>
humans, dogs, cats, rabbits, hamsters, rats, mice or the like, the administration regimen,<br>
formulation and dosage for application to humans will be particularly explained below.<br>
[0074] The agents of the present invention may be administered orally or parenterally, and<br>
tablets, coated-tablets, powdered drugs, granules, capsules, microcapsules, syrups or the<br>
like may be used as the dosage form for oral administration whereas eye drops, inhalants,<br>
injectable form (including lyophilizates for injection which are to be dissolved upon<br>
application), suppositories, poultices or the like may be used as the dosage form for<br>
parenteral administration. The formulation of these dosage forms may be effected using<br>
pharmaceutically acceptable excipients, binders, lubricants, disintegrants, suspending<br>
agents, emulsifiers, preservatives, stabilizing agents and dispersants, such as lactose,<br>
sucrose, starch, dextrin, crystalline cellulose, kaolin, calcium carbonate, talc, magnesium<br>
stearate, distilled water or saline.<br>
[0075] When used in oral dosage forms, the dosages of the effective ingredient will differ<br>
depending on the symptoms, age, weight or the like of the patient, but a daily dose of 10-<br>
500 mg may be administered in 2-3 portions for an adult weighing 60 kg. In addition, the<br>
dosages will also differ depending on the symptoms of the patient in the case of<br>
ophthalmic solutions, inhalation to lungs or the nasal cavity, and injection to inflamed<br>
articular cavities, but a daily dose of 1-100 g may be administered in 2-3 portions for an<br>
adult.<br>
EXAMPLES<br>
[0076] PRODUCTION EXAMPLES<br>
Some examples of the heterocyclic compounds represented by the general Formula (I)<br>
were produced according to the processes disclosed in the examples of Patent Documents<br>
3, 4 and 5, and described below.<br>
[0077] The synthesis was preformed with reference to Patent Documents 1-3.<br>
[0078] Production Example 1<br>
2-(2-Methylbenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine (Compound 1)<br>
Melting point: 218-20C (Decomposed)<br>
NMR(CDCl3): 3.03 (3 H, s), 3.7-3.9 (16H, m), 7.2-7.4 (2H, m), 7.7-7.8 (1H, m), 8.1-8.3<br>
(lH,m)<br>
28<br><br>
MS m/z:381(M+)<br>
[0079] Production Example 2<br>
2-(Benzimidazol-l-yl)-4-(trans-2,3-dimethylmorpholino)-6-morpholino-l,3,5-triazine<br>
(Compound 2)<br>
Melting point: 147-150 C<br>
NMR(CDCl3) : 1.1-1.5(6H, m), 2.7-3.0(lH, m), 3.4-3.6(lH, m), 3.7-4.0(8H, m), 4.1-<br>
4.3(1H, m), 4.4-4.7(2H, m), 7.3-7.4(2H, m), 7.7-7.9(lH, m), 8.3-8.4(lH, m), 8.98(1H, s).<br>
[0080] Production Example 3<br>
4,6-Dimorpholino-2-(2-hydroxymethylbenzimidazol-l-yl)-l,3,5-triazine (Compound 3)<br>
Melting point: 208-210 C (Decomposed)<br>
NMR(CDC13) : 3.7-3.9(16H, m), 4.59(1H, t, J=6Hz), 5.15(2H, d, J=7Hz),7.2-7.4(2H, m),<br>
7.7-7.8(lH, m), 8.3-8.4( lH, m)<br>
MS m/z : 397(M+)<br>
[0081] Production Example 4<br>
2-(2-Difluoromethylbenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine (Compound 4)<br>
Melting point: 211-214 C<br>
NMR(CDC13): 3.79(8H, t, J=4Hz), 3.88(8H, t, J=4Hz), 7.3-7.4(2H, m), 7.56(1H, t,<br>
J=53Hz), 7.88(1H, d, J=7Hz), 8.32(1H, d, J=7Hz).<br>
MS m/z: 417(M+)<br>
[0082] Production Example 5<br>
2-(2-Aminobenzimidazol-l -yl)-4,6-dimorpholinopyrimidine (Compound 5)<br>
Melting point: 237-239 C<br>
NMR(CDCl3): 3.59(8H, t, J=5Hz), 3.84(8H, t, J=5Hz), 5.46(1H, s), 6.65(2H, brs),<br>
7.06(lH, t, J=7Hz), 7.18(1H, t, J=7Hz), 7.37(1H, d, J=7Hz), 8.1(1H, d, 7Hz)<br>
MSm/z:381(M+)<br>
[0083] Production Example 6<br>
2-(2-Aminobenzimidazol-1 -yl)-4,6-dimorpholino-1,3,5-triazine (Compound 6)<br>
Melting point: 298-300 C (Decomposed)<br>
NMR(CDCl3): 3.7-3.9(16H, m), 6.74(2H, brs), 7.05(lH, t, J=7Hz), 7.20(1H, t, J=7Hz),<br>
7.39(1H, d, J=7Hz), 8.20(1H, d, 7Hz)<br>
MS m/z : 382(M+)<br>
[0084] Production Example 7<br>
2-(2-Difluoromethylbenzimidazol-l-yl)-4-piperidino-6-morpholino-l,3,5-triazine<br>
(Compound 7)<br>
29<br><br>
Melting point: 190-192 C<br>
NMR(CDCl3): 1.5-1.8(6H, m), 3.7-3.9(12H, m), 7.3-7.5(2H, m), 7.61(1H, t, J=54Hz),<br>
7.90(1H, d, J=8Hz), 8.34(1H, d, 8Hz)<br>
MSm/z : 415(M+)<br>
[0085] Production Example 8<br>
2-(6-Amino-2-difluoromethylbenzimidazol-l-yl)-4-(cis-2,3-dimethylmorpholino)-6-<br>
morpholino-l,3,5-triazine (Compound 8)<br>
Melting point: 220-222 C (Decomposed)<br>
NMR(CDCl3): 1.22(3H, d, J=9Hz), 1.26(3H, d, J=9Hz), 3.1-3.4(1H, m), 3.5-4.1(11H, m),<br>
4.3-4.5(lH, m), 4.5-4.7(lH, m), 6.77(1H, dd, J=2Hz, J=9Hz), 7.49(1H, t, J=54Hz),<br>
7.62(1H, d, J=9Hz), 7.64(1H, d, J=2Hz).<br>
MSm/z: 460(M+)<br>
[0086] Production Example 9<br>
2-(2-Difluoromethyl-6-ethoxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 9)<br>
Melting point: 222-224 C<br>
NMR(CDC13): 1.46(3H, t, J=7Hz), 3.7-3.9(16H, m), 4.08(2H, q, J=7Hz), 7.00(lH, dd,<br>
J=9Hz, 3Hz), 7.52(1H, t, J=54Hz), 7.74(1H, d, J=9Hz), 7.89(1H, d, J=3Hz).<br>
MSm/z : 461(M+)<br>
[0087] Production Example 10<br>
2-(2-Difluoromethyl-4-methylbenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 10)<br>
Melting point: 259-260 C<br>
NMR(CDCl3): 2.72(3H, s), 3.7-3.9(16H, m), 7.1-7.5(2H, m), 7.56(1H, t, J=54Hz),<br>
8.15(lH,d,8Hz)<br>
MSm/z : 431(M+)<br>
[0088] Production Example 11<br>
2-(2-Difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-morpholino-6-(2,6-<br>
dimethylmorpholino)pyrimidine (Compound 11)<br>
Melting point: 265-267 C<br>
1H NMR(CDCl3): 3.7-3.9(16 H, m), 3.86 (3 H , s), 7.02 (1 H , dd, J = 3, 9 Hz,), 7.52 (1<br>
H, t, J = 53 Hz,), 7.75 (1 H , d, J = 9 Hz,),7.91 (1 H, d, J = 3Hz,),.<br>
MS m/z 447 (M+).<br>
[0089] Production Example 12<br>
30<br><br>
2-(2-Difluoromethyl-5-hydroxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 12)<br>
Melting point: 272-274 C<br>
NMR(CDC13): 3.7-3.9(16H, m), 7.26-7.29(2H, m), 7.54(1H, t, J=54Hz), 8.20(1H, d,<br>
8Hz)<br>
MS m/z: 433(M+)<br>
[0090] Example 13<br>
2-(6-Amino-2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholino-l,3,5-triazine (Compound 13)<br>
Melting point: 226-227 C (Decomposed)<br>
NMR(CDCl3): 1.28(6H, s), 3.6-3.8(14H, m), 6.7-6.8(lH, m), 7.2-7.7(3H, m).<br>
MS m/z: 460(M+)<br>
[0091] Example 14<br>
2-(4-Amino-2-difluoromethylbenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 14)<br>
Melting point: 214-216 C (Decomposed)<br>
NMR(CDCl3): 3.7-3.9(16H, m), 4.48(2H, brs), 6.63(1H, d, J=8Hz), 7.21(1H, t, J=8Hz),<br>
7.55(1H, t, J=54Hz), 7.64(1H, d, J=8Hz).<br>
MS m/z: 432(M+)<br>
[0092] Production Example 15<br>
2-(2-Difluoromethyl-4-hydroxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 15)<br>
Melting point: &gt;250 C<br>
NMR(DMSO-d6): 3.70-3.90(16H,m), 6.76(1H, d, J=8Hz), 7.73(1H, t, J=8Hz), 7.70(1H,<br>
t, J=54Hz), 7.74(1H, d, J=8Hz),10.24 (1H, brs)<br>
MS m/z: 433<br>
[0093] Production Example 16<br>
2-(2-Difluoromethyl-6-hydroxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 16)<br>
Melting point: &gt;250 C<br>
NMR(DMSO-d6): 3.70-3.90(16H,m), 6.86(lH,d,J=8Hz), 7.61(lH,d,J=8Hz),<br>
7.70(lH,t,J=54Hz), 7.73(lH,s), 9.81 (lH,brs)<br>
MS m/z: 433<br>
[0094] Production Example 17<br>
31<br><br>
2-(5-Amino-2-difluoromethylbenzimidazol-l-yl)-4,6-di(2,6-dimethylmorpholino)-<br>
pyrimidine (Compound 17)<br>
Melting point: 157-160 C<br>
NMR(CDCl3): 1.30(6H, d, J=9Hz), 2.6-2.8(4H, m), 3.6-4.2(8H, m), 5.45(1H, s), 6.7-<br>
6.8(1H, m), 7.5-7.7(2H, m), 7.42(1H, t, J=53Hz)<br>
MS m/z: 487(M+)<br>
[0095] Production Example 18<br>
2-(2-Difluoromethyl-4-hydroxybenzimidazol-l-yl)-4,6-dimorpholinopyrimidine<br>
(Compound 18)<br>
Melting point: &gt;250 C<br>
NMR(DMSO-d6): 3.60-3.80(16H,m), 5.98(lH,s), 6.72(lH,d,J=8Hz), 7.22(lH,t,J=8Hz),<br>
7.62(1H, d,J=8Hz) ,7.65(lH,t,J=54Hz), 10.17 (lH,brs)<br>
MS m/z: 432<br>
[0096] Production Example 19<br>
2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholino-l,3,5-triazine (Compound 19)<br>
(1)	6-Amino-4-chloro-2-difluoromethylbenzimidazole (500 mg, 2.3 mmol) was<br>
dissolved in acetone (50 ml), 2,4-dichloro-6-morpholino-l,3,5-triazine (542 mg, 2.3<br>
mmol) was added at -15C, and potassium carbonate (500 mg) was further added. After<br>
having elevated the temperature gradually to room temperature, the mixture was stirred at<br>
room temperature for 5 hours. The solvent was evaporated under vacuum, and the residue<br>
was purified by silica gel column chromatography (n-hexane : ethyl acetate =1 : 4) to<br>
afford 2-(6-amino-4-chloro-2-difluoromethylbenzimidazol-1 -yl)-4-chloro-6-morpholino-<br>
1,3,5-triazine (272 mg, yield 28%).<br>
(2)	2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-1 -yl)-4-chloro-6-morpholino-<br>
1,3,5-triazine (150 mg, 0.36 mmol) thus obtained was dissolved in DMF (6ml), 2,2-<br>
dimethylmorpholine hydrochloride (150 mg, 1.0 mmol) was added thereto at -15C, and<br>
potassium carbonate (500 mg) was further added. After stirring at room temperature<br>
overnight, water was added to the reaction mixture, which was extracted with ethyl acetate<br>
several times, washed with brine, and dried over anhydrous magnesium sulfate. After the<br>
solvent was evaporated under vacuum, the residue was purified by silica gel column<br>
chromatography (n-hexane : ethyl acetate = 1 : 2) to give the title compound as colorless<br>
crystals (130 mg, yield 73%).<br>
Melting point: 238 C (Decomposed)<br>
32<br><br>
NMR (CDCl3): 1.27 (6H, s), 3.68 (2H, s), 3.7-3.9 (12H, m), 6.82 (1H, d, J =2.3Hz), 7.42<br>
(1H, dt, J =9.6Hz, J =53Hz), 7.50 (1H, d, J =2.3Hz)<br>
MS m / z: 494 (M +)<br>
[0097] Production Example 20<br>
2-(2-Difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(2-hydroxymethylpyrrolidin-1 -yl)-6-<br>
morpholino-l,3,5-triazine (Compound 20)<br>
Melting point: 245 C (Decomposed)<br>
NMR (CDCl3): 1.9-2.1(4H, m), 3.5-4.0(12H, m), 4.7-4.8(lH, m), 5.1-5.3(1H, m),<br>
6.89(1H, d, J=9Hz), 7.30(1H, t, J=9Hz), 7.50(1H, brs), 7.55(1H, t, J=54Hz), 7.83(1H, d,<br>
J=9Hz).<br>
MS m/z: 447(M+)<br>
[0098] Production Example 21<br>
2-(2-Difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholinopyrimidine (Compound 21)<br>
Melting point: 185-187 C<br>
NMR (CDCl3): 1.29(6H, s), 3.48(2H, s), 3.59-3.64(6H, m), 3.81-3.87(6H, m), 5.47(1H,<br>
s), 6.86(1H, m), 7.26-7.32(lH, m), 7.49(1H, t, J=53Hz), 7.72(1H, d, 8Hz)<br>
MS m/z : 460(M+)<br>
[0099] Production Example 22<br>
2-(2-Difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-(3,3-dimethylmorpholino)-6-<br>
morpholinopyrimidine (Compound 22)<br>
Melting point: 204-206 C<br>
NMR (CDCl3): 1.48(6H, s), 3.50(2H, s), 3.6-3.8(6H, m), 3.8-4.0(6H, m), 5.76(1H, s),<br>
6.68(1H, d, J=7Hz), 7.29(1H, d, J=7Hz), 7.49(1H, t, J=54Hz), 7.66(1H, d, 7Hz)<br>
MS m/z : 460(M+)<br>
[00100] Production Example 23<br>
2-(2-Difluoromethyl-5-methoxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(Compound 23)<br>
Melting points: 206-207 C<br>
NMR((CD3)2CO) : 1.17 (6H, d, J=6Hz), 2.5-2.8(4H, m), 3.6-4.4(10H, m), 5.95(1H, s),<br>
6.77(1H, d, J=8Hz), 7.23(1H, t, J=8Hz), 7.66(1H, t, J=53Hz), 7.75(1H, d, J=8Hz), 8.9(1H,<br>
s)<br>
MS m/z 447 (M+)<br>
[00101] Production Example 24<br>
33<br><br>
2-(2-Difluoromethyl-4-methoxybenzimidazol-l-yl)-4-(cis-2,6-dimethylmorpholino)-6-<br>
morpholinopyrimidine (Compound 24)<br>
(1)	2-Difluoromethyl-4-methoxybenzimidazole (9.03 g, 45.6 mmol) was dissolved in<br>
DMF (100 ml), 60% NaH (1.82 g, 45.6 mmol) was added, and stirred for 30 minutes. The<br>
reaction mixture was added to a solution obtained by dissolving 2,4,6-trichloropyrimidine<br>
(15.7 g, 92.1 mmol) into DMF (100 ml) while cooling with ice, and stirred on an ice bath<br>
for 30 minutes and further at room temperature for 2 hours. Water was added to the<br>
reaction mixture, precipitated crystals were filtered, and washed well with hexane and<br>
ether, then air-dried to afford 2-(2-difluoromethyl-4-methoxybenzimidazol-l-yl)-4,6-<br>
dichloropyrimidine (12.3g, yield 78%).<br>
(2)	2-(2-Difluoromethyl-4-methoxybenzimidazol-l-yl)-4,6-dichloropyrimidine (12.3 g,<br>
35.7 mmol) thus obtained was dissolved in DMF (150 ml), cis-2,6-dimethylmorpholine<br>
(6.63 ml, 53.7 mmol) was added at room temperature, and potassium carbonate (7.35 g)<br>
was further added. After stirring at room temperature for 30 minutes, water was added to<br>
the reaction mixture, extracted with ethyl acetate several times, washed with brine, and<br>
dried over anhydrous magnesium sulfate. After the solvent was evaporated under vacuum,<br>
the residue was washed sufficiently with hexane, and then successively with ether, and<br>
then air-dried to give 4-chloro-2-(2-difluoromethyl-4-methoxybenzimidazol-l-yl)-6-(cis-<br>
2,6-dimethyl-morpholino)pyrimidine (14.4 g, yield 95%).<br>
(3)	Morpholine (275 ml, 3.15 mol) was added to 4-chloro-2-(2-difluoromethyl-4-<br>
methoxybenzimidazol-l-yl)-6-(cis-2,6-dimethylmorpholino)pyrimidine (14.4 g, 34 mmol)<br>
thus obtained, and stirred at room temperature for 30 minutes and further at 80C for 30<br>
minutes. Water was added to the reaction solution, and the precipitated crystals were<br>
filtered, and washed well successively with hexane, ether and ethyl acetate, then air-dried<br>
to afford 2-(2-difluoromethyl-4-methoxybenzimidazol-1 -yl)-4-(cis-2,6-dimethyl-<br>
morpholino)-6-morpholinopyrimidine (13.7 g, yield 86%).<br>
Melting point: 180-181 C<br>
NMR(CDCl3) : 1.28(6H, d, J=6Hz), 2.6-2.7(2H, m), 3.6-3.7(6H, m), 3.80-3.86(4H, m),<br>
4.04(3H, s), 4.10-4.14(2H, m), 5.49(1H, s), 6.78(1H, d, J=8Hz), 7.32(1H, d, J=8Hz),<br>
7.41(1H, t, J-52Hz), 7.77(1H, d, J=8Hz)<br>
MS m/z: 474(M+)<br>
[00102] Production Example 25<br>
2-(2-Difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(5-oxo-1,4-diazepan-1 -yl)-1,3,5-<br>
triazine (Compound 25)<br>
34<br><br>
Melting point: 235-37 C<br>
1H NMR(CDCl3) : 2.7-2.8 (2H, m), 3.4-3.5 (2H, m), 3.8-4.2 (12H, m), 5.97 (1H, brs),<br>
7.2-7.5 (2 H, m), 7.52 (1 H, t, J = 54Hz), 7.8-8.0 (1 H, m) 8.2-8.4 (1 H ,m).<br>
MS m/z 444 (M+)<br>
[00103] Production Example 26<br>
2-(2-Difluoromethylbenzimidazol-1 -yl)-4-(4-hydroxypiperizin-1 -yl)-6-morpholino-1,3,5-<br>
triazine (Compound 26)<br>
Melting point: 219-21 C<br>
1HNMR(CDCl3) : 3.4-3.5 (2H, m), 3.7-4.1 (16H, m), 7.3-7.5 (2 H, m), 7.59 (1 H, t, J =<br>
50Hz), 7.8-8.0 (1 H, m) 8.3-8.4 (1 H ,m).<br>
MS m/z 431 (M+).<br>
[00104] Production Example 27<br>
2-(2-Difluoromethylbenzimidazol-1 -yl)-4- [4-(2-hydroxyethyl)piperazin-1 -yl] -6-<br>
morpholino-l,3,5-triazine (Compound 27)<br>
Melting point: 174-77 C<br>
1H NMR(CDCl3) : 2.6-2.7 (8H, m), 3.6-3.9 (12H, m), 3.91 (1H, br) 7.3-7.5 (2 H, m),<br>
7.58 (1 H, t, J = 54Hz), 7.9-8.0 (1 H, m) 8.3-8.4 (1 H ,m).<br>
MS m/z 460 (M+).<br>
Refer to Patent Document 4.<br>
[00105] Production Example 28<br>
2-(2-Difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(2-hydroxymethylpyrrolidin-1 -yl)-6-<br>
morpholinopyrimidine (947)<br>
(1)	4-rert-Butyldimethylsilyloxy-2-difluoromethylbenzimidazole (1.49 g, 5.0 mmol)<br>
was dissolved in DMF (10 ml), 2,4,6-trichloropyrimidine (0.91 g, 5.0 mmol) was added at<br>
room temperature, potassium carbonate (0.55 g) was further added, and the mixture was<br>
stirred for 5 hours. Water was added to the reaction mixture, extracted with ethyl acetate<br>
several times, washed with brine, and then dried over anhydrous magnesium sulfate. After<br>
the solvent was evaporated under vacuum, the residue was purified by silica gel column<br>
chromatography (n-hexane : ethyl acetate = 8 : 1) to give 2-(4-tert-buthyldimethylsilyloxy-<br>
2-difluoromethylbenzimidazol-l-yl)-4,6-dichloropyrimidine (1.12 g, yield 50%).<br>
(2)	2-(4-tertButhyldimethylsilyloxy-2-difluoromethylbenzimidazol-1 -yl)-4,6-<br>
dichloropyrimidine (386 mg, 0.87 mmol) thus obtained was dissolved in DMF (6 ml), 2-<br>
pyrrolidine methanol (0.13 ml, 1.3 mmol) was added at room temperature, and potassium<br>
carbonate (179 mg) was further added. After the mixture was stirred at room temperature<br>
35<br><br>
for 30 minutes, water was added to the reaction mixture, extracted with ethyl acetate<br>
several times, washed with brine, and dried over anhydrous magnesium sulfate. After the<br>
solvent was evaporated under vacuum, the residue was purified by silica gel column<br>
chromatography (n-hexane : ethyl acetate =1 : 1) to give 2-(4-tert-buthyldimethylsilyloxy-<br>
2-difluoromethylbenzimidazol-1 -yl)-4-(2-hydroxy-methylpyrrolidin-1 -yl)-6-<br>
chloropyrimidine (291 mg, yield 64%).<br>
(3) Morpholine (4.4 g, 50 mmol) was added to 2-(4-tert-buthyldimethylsilyloxy-2-<br>
difluoromethylbenzimidazol-1 -yl)-4-(2-hydroxymethyl-pyrrolidin-1 -yl)-6-<br>
chloropyrimidine (281 mg, 0.54 mmol) thus obtained, and the mixture was stirred at room<br>
temperature for 9 hours. Water was added to the reaction mixture, extracted with ethyl<br>
acetate several times, washed with brine, and then dried over anhydrous magnesium<br>
sulfate. After the solvent was evaporated under vacuum, the residue was purified by silica<br>
gel column chromatography (n-hexane : ethyl acetate = 2 : 3) to obtain 2-(4-tert-<br>
bumyldimethylsilyloxy-2-difluoromethylbenzimidazol-l-yl)-4-(2-hydroxy-<br>
methylpyrrolidin-l-yl)-6-morpholinopyrimidine (216 mg, yield 72%).<br>
2-(4-tert-Buthyldimethylsilyloxy-2-difluoromethyl-benzimidazol-l-yl)-4-(2-<br>
hydroxymethylpyrrolidin-l-yl)-6-morpholinopyrimidine (213 mg, 0.38 mmol) was<br>
dissolved in anhydrous THF (7 ml), tetra-n-butylammonium fluoride (0.4 ml) (1M THF<br>
solution) was added at room temperature, and the mixture was stirred for 30 minutes.<br>
Water was added to the reaction mixture, extracted with ethyl acetate several times,<br>
washed with brine, and dried over anhydrous magnesium sulfate. After the solvent was<br>
evaporated under vacuum, the residue was purified by silica gel column chromatography<br>
(n-hexane : ethyl acetate = 1 : 4) to obtain the title compound as colorless crystals (101 mg,<br>
yield 60%).<br>
Melting point: 195-198C<br>
NMR(CDCl3): 2.0-2.1(4H, m), 3.4-4.0(12H, m), 4.0-4.1(lH, m), 4.3-4.4(lH, m),<br>
5.36(1H, s), 6.85(1H, d, J=8Hz), 7.28(1H, t, J=8Hz), 7.58(1H, brs), 7.58(1H, t, J=54Hz),<br>
7.73(1H, d, J=8Hz).<br>
MSm/z: 446(M+)<br>
The production was effected with reference to Patent Document 4.<br>
[00106] Production Example 29<br>
2-(5,6-Dimethyl-2-difluoromethylbenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine<br>
(ZSTK705)<br>
Melting point: 217-220C<br>
36<br><br>
1H NMR (CDCl3) : 2.39 (3H, s), 2.40 (3H, s), 3.7-3.9 (16H, m), 7.53 (1 H, t, J = 54Hz),<br>
7.62 (lH, s) 8.12 (lH, s).<br>
MS m/z 445 (M+).<br>
[00107] Production Example 30<br>
2-(6-Amino-4-chloro-2-difluoromethylbenzimidazol-l-yl)-4-(2-hydroxymethylpyrrolidin-<br>
1-yl )-6-morpholino-l,3,5-triazine (STK922)<br>
Melting point: 256C (Decomposed)<br>
NMR(CD3OD-CDCl3(1:1)) : 1.9-2.2(4H, m), 3.68(2H, s), 3.5-4.0(llH, m), 4.39(1H,<br>
brs), 6.84(1H, d, J=2.1Hz), 7.58(1H, t, J=53Hz), 7.64(1H, d, J=2.1Hz).<br>
MS m/z: 480(M+)<br>
[00108] Production Example 31<br>
2-(4-Chloro-2-difluoromethyl-5-hydroxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-<br>
triazine (STK894)<br>
Melting point: &gt;250C<br>
NMR(CDC13): 3.7-3.9(16H, m), 5.63(1H, s), 7.15(1H, d, J=9Hz), 7.51(1H, t, J=53Hz),<br>
8.14(lH,d,J=9Hz).<br>
MS m/z: 467(M+)<br>
[00109] Production Example 32<br>
Synthesis of 4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-<br>
morpholino-l,3,5-triazine (Compound 28)<br>
A mixture of 6-chloro-2-(2-difmoromethylbenzimidazol-l-yl)-4-morpholino-l,3,5-<br>
triazine (3.66 g, 10 mmol), 1-acetylpiperazine (1.40 g, 11 mmol), potassium carbonate<br>
(1.38 g, 10 mmol) and DMF (30 ml) was stirred at room temperature for 16 hours. The<br>
reaction mixture was poured into water, and extracted with dichloromethane. The extract<br>
was dried over anhydrous sodium sulfate, concentrated under vacuum, and the residue was<br>
purified by silica gel column to obtain 4-(4-acetylpiperazin-l-yl)-2-(2-<br>
difluoromethylbenzimidazol-l-yl)-6-morpholino-l,3,5-triazine (4.08 g, 9.0 mmol) in a<br>
yield of 90% as colorless crystals.<br>
Naturally, triazine or pyrimidine derivatives bearing such piperazine groups may also<br>
be synthesized according to the following schemes.<br>
For example, a mixture of 6-chloro-2-(2-difluoromethylbenzimidazol-l-yl)-4-<br>
morpholino-l,3,5-triazine (3.66 g, 10 mmol), piperazine (3.45 g, 40 mmol), and acetone<br>
(50 ml) was stirred at room temperature for 16 hours. The reaction mixture was poured<br>
into water, and precipitated crystals were filtered, and washed with methanol to afford 2-<br>
37<br><br>
(2-difluoromethylbenzimidazol-1-yl)-4-morpholino-6-(piperazin-1 -yl)-1,3,5-triazine (3.87<br>
g, 9.3 mmol) in a yield of 93% as colorless crystals.<br>
1H NMR (CDCl3) : 3.8-4.1 (16H, m), 7.3-7.5 (2 H, m), 7.59 (1 H, t, J = 54Hz), 7.9-8.0 (1<br>
H, m) 8.3-8.4 (1 H, m).<br>
MSm/z416(M+).<br>
Acetyl chloride (0.14 ml, 2.0 mmol) was added dropwise to a mixture of 2-(2-<br>
difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(piperazin-1 -yl)-1,3,5 -triazine (417 mg,<br>
1.0 mmol) and THF (10 ml). The reaction mixture was stirred at room temperature for 22<br>
hours. The reaction mixture was poured into water, and extracted with dichloromethane.<br>
The extract was dried over anhydrous sodium sulfate, concentrated under vaccum, and the<br>
residue was purified by silica gel column to give the target compound 4-(4-<br>
acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-morpholino-1,3,5 -triazine<br>
(354 mg, 7.7 mmol) in a yield of 77% as colorless crystals.<br>
Melting point: 223C<br>
1H NMR (CDCl3) 8: 2.18 (3 H, s), 3.6-4.0 (16H, m), 7.3-7.5 (2 H, m), 7.55 (1 H, t, J =<br>
53.5 Hz), 7.9-8.0 (1 H, m) 8.3-8.4 (1 H ,m).<br>
MS m/z 458 (M+).<br>
The following compounds were manufactured in a manner similar to Production<br>
Example 34.<br>
[00110] Production Example 33<br>
2-(2-Difluoromethylbenzimidazol-l-yl)-6-(4-formylpiperazin-l-yl)-4-morpholino-l,3,5-<br>
triazine<br>
Melting point: 228-30C<br>
1H NMR (CDCl3) : 3.8-4.1 (16H, m), 7.2-7.5 (2 H, m), 7.54 (1 H, t, J = 54Hz), 7.8-8.0 (1<br>
H, m), 8.17 (1H, s), 8.3-8.4 (1 H ,m).<br>
MS m/z 444 (M+).<br>
[00111] Production Example 34<br>
2-(2-Difluoromethylbenzimidazol-l-yl)-4-morpholino-6-(3-oxopiperazin-l-yl)-l,3,5-<br>
triazine<br>
Melting point: 255-57C<br>
lH NMR (CDCl3) : 3.5-3.9 (14H, m), 6.48 (1H, brs), 7.2-7.5 (2 H, m), 7.59 (1 H, t, J =<br>
54Hz), 7.8-7.9(1 H, m) 8.2-8.4 (1 H ,m).<br>
MS m/z 430(M+).<br>
[00112] Production Example 35<br>
38<br><br>
2-(2-Difluoromethylbenzimidazol-l-yl)-6-(3,5-dioxopiperazin-l-yl)-4-morpholino-l,3,5-<br>
triazine<br>
Melting point: 230-32C<br>
1H NMR (CDCl3) : 3.5-3.9 (12H, m), 7.2-7.5 (2 H, m), 7.59 (1 H, t, J = 55Hz), 7.9-8.0 (1<br>
H, m) 8.3-8.4 (1 H ,m).<br>
MS m/z 444 (M+).<br>
[00113] Production Example 36<br>
2-(2-Difluoromethylbenzimidazol-1 -yl)-4-(4-benzylcarbonylpiperazin-1 -yl)-6-<br>
morpholino-l,3,5-triazine (Compound 29)<br>
(STK1515)<br>
Melting point: 178-181C<br>
1H NMR (CDCl3) : 3.81 (2 H , s), 3.5-3.9(16 H, m), 7.2-7.5(7 H, m), 7.52 (1 H, t, J = 54<br>
Hz,), 7.89 (1 H , d, J = 8 Hz,),8.30 (1 H , d, J = 8 Hz,).<br>
MS m/z 534 (M+).<br>
[00114] Production Example 37<br>
4-(4-Acetonylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-morpholino-1,3,5-<br>
triazine (Compound 30) (STK01529)<br>
Melting point: 79-81C<br>
NMR (CDCl3-d1): 2.19 (3H, s) ,2.60(2H,s), 3.70-4.00(16H,m), 7.30-7.50(2H,m),<br>
7.57(1 H,t,J=54Hz), 7.90(1H, d ,J=8Hz),8.33(lH, d ,J=8Hz)<br>
MS m/z: 472<br>
[00115] Production Example 38<br>
2-(2-Difluoromethylbenzimidazol-1 -yl)-4-[4-(2-furoyl)piperazin-1 -yl]-6-morpholino-<br>
1,3,5-triazine (Compound 31) (STK01531)<br>
Melting point: 220-222C<br>
NMR (CDCl3-d1): 3.80-4.00(16H,m), 6.53(1H, d ,J=2Hz), 7.01(lH, d ,J=2Hz), 7.30-<br>
7.60(4H,m),7.80(lH, d, J=8Hz), 8.34(1H, d, J=8Hz)<br>
MS m/z : 510<br>
[00116] Production Example 39<br>
2-(2-Difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin-l-yl)-6-<br>
morpholino-l,3,5-triazine (Compound 32) (STK01539)<br>
Melting point: 203-205C<br>
NMR (CDCl3-d1): 2.90(6H,s),3.30-3.40(4H,m),3.80-4.00(12H,m), 7.30-7.40(2H,m),<br>
7.56(lH,t,J=54Hz), 7.89(1H, d, 8Hz),8.34 (1H, d, 8Hz)<br>
39<br><br>
MS m/z : 487<br>
[00117] Production Example 40<br>
2-(2-Difluoromethylbenzimidazol-1 -yl)-4-(4-methoxylacetylpiperazin-1 -yl)-6-<br>
morpholino-l,3,5-triazine (Compound 33) (STK01540)<br>
Melting point: 72-75C<br>
NMR (CDCl3-d1): 3.46(3H, s), 3.60-4.00(16H,s), 4.17 (2H, s) 7.30-7.50(2H,m),<br>
7.55(lH,t,J=54Hz), 7.90(1H, d, J=8Hz), 8.34(1H, d, J=8Hz)<br>
MS m/z: 488<br>
[00118] Production Example 41<br>
2-(2-Difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazin-1 -yl] -6-<br>
morpholino-l,3,5-triazine (Compound 34) (STK01541)<br>
NMR (CDCl3-d1) : 1.17 (2H, m) ,2.60-2.70(4H, m), 4.70 (lH,brs) 3.50-4.00(16H,m),<br>
7.30-7.50(2H,m), 7.56(lH,t,J=54Hz), 7.90(1H, d, J=8Hz),8.33(lH, d, J=8Hz)<br>
MS m/z: 474<br>
[00119] Production Example 42<br>
2-(2-Difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -yl)-<br>
1,3,5-triazine (Compound 35) (STK01542)<br>
Melting point: 198-202C<br>
NMR (CDCl3-d1) : 1.20 (3H, t,J=7Hz) ,2.42(2H, q ,J=7Hz), 3.50-4.00(16H,m), 7.30-<br>
7.50(2H,m), 7.56(lH,t,J=54Hz), 7.90(1H, d, J=8Hz),8.33(lH, d, J=8Hz)<br>
MS m/z: 472<br>
[00120] Production Example 43<br>
2-(2-Difluoromethylbenzimidazol-1-yl)-4-(4-methoxycarbonylpiperazin-1-yl)-6-<br>
morpholino-l,3,5-triazine(STK01553)<br>
Melting point: 255-260C<br>
NMR (CDCl3-d1) : 3.59(4H,brs), 3.76(3H,s),3.70-3.95(12H,s), 7.30-7.50(2H,m),<br>
7.55(1 H,t,J=54Hz), 7.9O(1H, d, J=8Hz),8.34(lH, d, J=8Hz)<br>
MS m/z: 474<br>
[00121] The following were produced in the same manner as in Production Example 24.<br>
Production Example 44<br>
2-(2-Difluoromethyl-4-methoxybenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholinopyrimidine (Compound 36)<br>
Melting point: 166-168C<br>
40<br><br>
NMR (CDCl3) : 1.30(6H, s), 3.49(2H, s), 3.4-3.9(12H, m), 4.05(3H, s), 5.47(1H, s),<br>
6.79(1H, d, J=8Hz), 7.32(1H, t, J=8Hz), 7.41(1H, t, J=54Hz), 7.78(1H, d, J=8Hz).<br>
MSm/z: 474(M+)<br>
[00122] Production Example 45<br>
2-(2-Difluoromethyl-4-methoxybenzimidazol-1 -yl)-4-(cis-2,3 -dimethylmorpholino)-6-<br>
morpholinopyrimidine (Compound 37)<br>
Melting point: 176-178C<br>
NMR (CDCl3) : 1.20(3H, d, J=5Hz), 1.22(3H, d, J=5Hz), 3.6-3.7(lH, m), 3.6-4.1(13H,<br>
m), 4.05(3H, s), 5.47(1H, s), 6.79(1H, d, J=8Hz), 7.32(1H, t, J=8Hz), 7.42(1H, t, J=53Hz),<br>
7.78(1H, d, J=8Hz).<br>
MS m/z: 474(M+)<br>
[00123] Production Example 46<br>
2-(2-Difluoromethyl-4-ethoxybenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholinopyrimidine (Compound 38)<br>
Melting point: 114-116C<br>
NMR (CDCl3) : 1.56(3H, t, J=7Hz), 3.49(2H, s), 3.5-3.9(12H, m), 4.32(2H, q, J=7Hz),<br>
5.47(1H, s), 6.78(1H, d, J=8Hz), 7.30(1H, t, J=8Hz), 7.41(1H, t, J=53Hz), 7.76(1H, d,<br>
J=8Hz).<br>
MS m/z: 488(M+)<br>
[00124] Drug Efficacy Assays<br>
Next, the assay protocols for pharmacological effects and toxicity of the heterocyclic<br>
compounds represented by the general Formula (I) and their results will be hereinafter<br>
described. Here, the compound number for each test substances corresponds to the<br>
compound number assigned to each of the above heterocyclic compounds.<br>
[00125] Assay Example 1<br>
Mitogen Response Inhibititory Activity<br>
Spleen cells (2 x 106 cells/mL) prepared from C57BL/6N female mice (8 weeks<br>
old, purchased from Charles River Laboratories Japan Inc.) were suspended in RPMI 1640<br>
medium (containing 10% fetal bovine serum, 10 mM HEPES, 1 mM pyruvic acid, 4.5 g/L<br>
glucose, 100 units/mL penicillin, and 0.1 mg/mL streptomycin), and seeded in wells of a<br>
96 well plate at 0.225 mL per well. Serial dilutions of test substances were added to<br>
respective wells, and then concanavalin A (Con A, 3 g/mL), lipopolysaccharide (LPS,<br>
100 g/mL), or an anti-mouse IgM antibody (100 g/mL) were added. Thereafter, they<br>
41<br><br>
were incubated under conditions of carbon dioxide 5 % at a temperature 37C for 3 days.<br>
Next, Alamar Blue solution was added at 50 L per 150 L, and after having cultured for<br>
one day, the fluorescence intensity at 590 nm using an excitation wavelength of 530 nm<br>
was determined by Cytoflour 4000 (Applied Biosystems). As a result, as shown in Table<br>
1, it was revealed that s-triazine analogs inhibit proliferation of mouse spleen cells induced<br>
by Con A, LPS, or an anti-IgM antibody.<br>
[00126] [Table 1]<br><br>
Test Compounds	Inhibition of<br>
Con A response	Inhibition of LPS<br>
response	Inhibition of Anti-IgM<br>
antibody response<br>
Compound 1	+	+	nd<br>
Compound 2	+	+	+<br>
Compound 3	+	+	nd<br>
Compound 4	++	++	++<br>
Compound 5	+	+	+<br>
Compound 6	+	+	+<br>
Compound 7	+	+	+<br>
Compound 8	++	+	++<br>
Compound 9	++	++	++<br>
Compound 10	+		+<br>
Compound 12	++	++	++<br>
Compound 13	++	++	++<br>
Compound 17	+		+<br>
Compound 19	++	++	nd<br>
Compound 20	+++	+++	+++<br>
Compound 21	+++	+++	+++<br>
Compound 22	+++	+++	+++<br>
Compound 24	+	+	+<br>
Compound 25	++	+	nd<br>
Compound 26	+++	++	nd<br>
Compound 27	+++	+	nd<br>
Compound 28	+++	++	nd<br>
42<br><br><br>
[00127] Assay Example 2<br>
Proliferation Inhibition Assay for Human Peripheral Blood Mononuclear Cells<br>
43<br>
4 mL of blood collected from healthy subjects was placed on 3 mL of MonoPoly<br>
Resolving Medium, and after centrifugation, the mononuclear cell (PBMC) fraction was<br>
collected. After washing with saline, PBMC (1 x 105 cells/mL) was suspended in RPMI<br>
1640 medium (containing 10% fetal bovine serum, 10 mM HEPES, 1 mM pyruvic acid,<br>
and 4.5 g/L glucose). Next, after having added an anti-CD28 antibody (1 g/mL) to the<br>
suspension, they were seeded on an anti-human CD3 T cell activation plate (BD<br>
Bioscience) at a capacity of 0.135 mL per well. Then, serial dilutions of test substances<br>
were added to respective wells, and incubated under conditions of carbon dioxide 5 % at a<br>
temperature 37C. After 3 days, Alamar Blue solution was added at 50 L per well, and<br>
after incubation for one day, a fluorescence intensity at 590 nm using an excitation<br>
wavelength of 530 nm was determined by Cytoflour 4000 (Applied Biosystems). As a<br>
result, as shown in Table 2, it was revealed that s-triazine analogs inhibit the growth of<br>
human T cells induced by an anti-CD3 antibody and an anti-CD28 antibody.<br>
[00128] [Table 2]<br><br><br><br>
[00129] Assay Example 3<br>
Activation Inhibition Assay for Human Peripheral Blood Mononuclear Cells<br>
In accordance with the method of Assay Example 2, PBMC (2 x 106 cells/mL) was<br>
isolated from human peripheral blood, suspended in RPMI 1640 medium (containing 10%<br>
fetal bovine serum, 10 mM HEPES, 1 mM pyruvic acid, and 4.5 g/L glucose), and seeded<br>
in wells of a 96 well plate at 0.225 mL per well. The test substances were added to<br>
respective wells, and then an anti-CD3 antibody (2 g/mL) and an anti-CD28 antibody (1<br>
g/mL) were added. Then, after incubation under conditions of carbon dioxide 5% at a<br>
temperature 37C for 6 hours, the expressions of CD40L and CD69, activation markers,<br>
were analysed by flow cytometry. As a result, when the cells were stimulated by both an<br>
anti-CD3 antibody and an anti-CD28 antibody, CD40L was expressed on 14.4% of PBMC,<br>
which was also CD4 positive. However, the proportion of the cells which expressed<br>
CD40L decreased when the cells had been treated with test substances (ZSTK474: 4.9%;<br>
913: 3.7%, 1213: 3.6%). Although CD69 was expressed on 28.8% (CD4-positive) and<br>
50.9% (CD4-negative) of PBMC, the proportions of CD4-positive cells (ZSTK 474:<br>
18.8%, 913: 10.1%, 1213:17.7%) and CD4-negative cells (ZSTK 474: 17.7%, 913: 10.5%,<br>
1213: 22.4%) which expressed CD69 decreased when the cells had been treated with test<br>
substances. Thus, the s-triazine analogs were shown to inhibit the activation of<br>
lymphocytes (Figure 1).<br>
[00130] Assay Example 4<br>
Adjuvant-Induced Arthritis Inhibitory Action<br>
Lyophilized Mycobacterium butyricum suspended in Freund's incomplete adjuvant<br>
was intradermally administered to the base of the tail of Lewis male rats (7 weeks old,<br>
purchased from Charles River Laboratories Japan Inc.) to induce adjuvant-induced<br>
arthritis. Then, 10 days after the induction of the adjuvant-induced arthritis, the test<br>
substances suspended in 0.5% hydroxypropylcellulose (HPC) were orally administered on<br>
consecutive days. Furthermore, after the onset of the arthritis, the volume of the hind paw<br>
was measured using a hindpaw edema volume measuring apparatus (TK105, Physio-Tech).<br>
As a result, for the test substances, as shown in Figure 2, a statistically significant<br>
44<br><br>
(analysis of variance, Dunnett's test P
after day 14 was confirmed for the present model study.<br>
[00131] Assay Example 5<br>
Collagen-Induced Arthritis Inhibitory Action<br>
Bovine type II collagen suspended in Freund's complete adjuvant was intradermally<br>
administered to the base of tail of DBA1 male mice (7 weeks old, purchased from Charles<br>
River Laboratories Japan Inc.) on day 1 and day 21. Then, from day 28 when 50% of the<br>
mice developed arthritis, the test substances suspended in 0.5% hydroxypropylcellulose<br>
(HPC) were orally administered on consecutive days. Here, the efficacy was evaluated by<br>
scoring the arthritis. Specifically, for each paw, the degree of arthritis was evaluated<br>
according to: no symptoms: 0; redness or swelling of one joint: 1; redness or swelling for<br>
two or more joints: 2; redness or swelling over the entire paw: 3; and maximum redness or<br>
swelling over the entire paw: 4. As a result, it was revealed that ZSTK474 inhibited the<br>
progression of the collagen-induced arthritis in a dose-dependent manner. For the group<br>
administered 50 or 100 mg/kg of the above compound, after day 30, a statistically<br>
significant efficacy was recognized (Dunnett's test P
administered 50 mg/kg of the above compound, the conditions were exacerbated after day<br>
40, and no significant difference was recognized in comparison with the control group<br>
after day 44 (Figure 3).<br>
[00132] Assay Example 6<br>
Inhibition Assay for Proliferation of Rabbit Synoviocyte<br>
Rabbit synoviocytes HIG-82 suspended in HAM medium (containing 10% fetal<br>
bovine serum, 25 mM HEPES, and 0.1 mg/mL kanamycin) (with 4 x 104 cells/mL) were<br>
seeded in wells of a 96 well plate at 0.135 mL per well. Then, 15 p.L of each of serial<br>
dilutions of test substances was added to a respective well, and incubated under conditions<br>
of carbon dioxide 5 % at a temperature 37C. Alamar Blue solution was added at 50 L<br>
per well on day 0 and day 3, and incubated for one day, and thereafter fluorescence<br>
intensity at 590 nm using an excitation wavelength of 530 nm was determined by<br>
Cytoflour 4000 (Applied Biosystems). As shown in Table 3, it was demonstrated that s-<br>
triazine analogs inhibited cell division of rabbit synoviocytes.<br>
45<br>
[00133] [Table 3]<br><br><br><br>
[00134] Assay Example 7<br>
Allogeneic Mixed Lymphocyte Reaction<br>
Spleen cells prepared from C57BL/6N female mice (8-10 weeks old, purchased from<br>
Charles River Laboratories Japan Inc.) and peripheral lymph node mononuclear cells<br>
prepared from BALB/c female mice (8-10 weeks old, purchased from Charles River<br>
Laboratories Japan Inc.) were used as stimulator cells and responder cells, respectively.<br>
The respective cells were suspended in RPMI 1640 medium (containing 10% fetal bovine<br>
serum, 100 units/mL penicillin, and 0.1 mg/mL streptomycin) (with 2 x 106 cells/mL).<br>
Then, the stimulator cells (50 uL) treated with mitomycin C (50 mg/mL, 30 minutes) were<br>
added to the responder cells (100 uL). Thereafter, serial dilutions of test substances were<br>
added to respective wells, and incubated under conditions of carbon dioxide 5% at 37C<br>
for 86 hours. Finally, the cell proliferation was examined using a BrdU cell proliferation<br>
kit (Calbiochem). As a result, as shown in Table 4, it was found that the s-triazine analogs<br>
inhibited the allogeneic mixed lymphocyte reaction.<br>
[00135] [Table 4]<br>
46<br><br><br>
[00136] Assay Example 8<br>
Proliferation Inhibitory Activity on Hematologic Neoplasm Cells<br>
Daudi cells (5 x 105 cells/mL), Jurkat cells (5 x 105 cells/mL), THP-1 cells (5 x 105<br>
cells/mL), U 937 cells (5 x 105 cells/mL), and HL 60 cells (5 x 105 cells/mL) suspended in<br>
RPMI 1640 medium (containing 10 % fetal bovine serum, 10 mM HEPES, 1mM pyruvic<br>
acid, 4.5 g/L glucose, 100 units/mL penicillin, and 0.1 mg/mL streptomycin) were seeded<br>
in 96 well plates at a capacity of 0.135 mL per well. Serial dilutions of test substances<br>
were added to respective wells at 15 L/well, and incubated under conditions of carbon<br>
dioxide 5 % at 37C for 3 days. Thereafter, Alamar Blue solution was added at 50 L, and<br>
after incubation for one day, the fluorescence intensity at 590 run using an excitation<br>
wavelength of 530 nm was determined by Cytoflour 4000 (Applied Biosystems). As a<br>
result, as shown in Table 5, it was revealed that s-triazine analogs inhibited the<br>
proliferation of hematologic neoplasm cells.<br>
47<br>
[00137] [Table 5]<br><br><br><br>
[00138] Assay Example 9<br>
Therapeutic Action on Human B Lymphoma Xenografted Model<br>
Daudi cells (1 x 107 cells/mL) cultured in RPMI 1640 medium (containing 10 % fetal<br>
bovine serum, 10 mM HEPES, lmM pyruvic acid, 4.5 g/L glucose, 100 units/mL<br>
penicillin, and 0.1 mg/mL streptomycin) were implanted subcutaneously in the chests of 8<br>
week-old NOD/SCID mice. After day 20 when the tumor had grown to the volume of<br>
about 800 mm3, Compound 8 (400 mg/kg) was administered orally. As a result, as shown<br>
in Figure 4, the increase in tumor volume in the present model was inhibited.<br>
[00139] Assay Example 10<br>
Fulminant Hepatitis Model<br>
BALB/c male mice (7 weeks old, purchased from Charles River Laboratories Japan<br>
Inc.) were used in the experiment. After having orally administered the test substances<br>
suspended in 5 % HPC, galactosamine (800 mg/kg) and LPS (110 g/kg) were<br>
intraperitoneally administered. Then, survival rates at 72 hours after administration were<br>
obtained. As a result, as shown in Table 6, the test substances improved the survival rate<br>
due to galactosamine and LPS.<br>
[00140] [Table 6]<br>
48<br><br><br>
[00141] Assay Example 11<br>
Toxicologic Test for Single Oral Administration<br>
A single oral dose toxicity of typical heterocyclic compounds was examined using SD<br>
male rats (6 weeks old, weight 162-188 g), and as a result, for Compound 8, no examples<br>
of death were recognized even with 1200 mg/kg, and for Compound 14, LD50 was 600-<br>
900 mg/kg.<br>
[00142] Assay Example 12<br>
Ames Test<br>
Using 5 strains of Salmonella typhimurium TA98, TA100, TA1535, TA1537 and<br>
Escherichia coli WP2uvrA, the test substances (Compound 8, Compound 10, Compound<br>
12 and Compound 14) were tested for their mutagenesis according to a preincubation<br>
method. As a result, with or without metabolic activation due to S-9, even in 5000 g/flat<br>
plate (maxium dose), no increase was observed in the colony number of reverse mutation<br>
in any tested strains, so mutagenesis was negative. Accordingly, in addition to in vivo<br>
tests such as rat adjuvant induced arthritis assay, mouse collagen induced arthritis assay,<br>
human B-lymphoma xenografted model, fulminant hepatitis inhibition assay and<br>
toxicologic test for single oral administration, s-triazine analogs were found to be safer<br>
compounds.<br>
[00143] The agents of the present invention inhibit the response to T cells and B cells<br>
induced by Con A, LPS, anti-IgM antibody, anti-CD3 antibody + anti-CD28 antibody,<br>
thereby exhibiting PI3K inhibitory action on immune cells. Specifically, the drugs of the<br>
present invention can be used in the treatment and prevention of disorders of immune<br>
system attributable to the hyperfunctioning of PI3K. As disorders of immune system<br>
attributable to the hyperfunctioning of PI3K, mention may be made of: autoimmune<br>
diseases such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, Sjogren<br>
49<br><br>
syndrome, or the like; organ dysfunction associated with autoimmune diseases such as<br>
uveitis, glomerulonephritis, thyroiditis, pancreatitis, bone destruction or the like; rejection<br>
after transplantation of tissues, graft versus host disease after bone-marrow<br>
transplantation; inflammatory bowel diseases such as ulcerative colitis or Crohn disease;<br>
inflammatory or allergenic skin diseases such as psoriasis or atopic dermatitis;<br>
inflammatory or allergenic respiratory disorders such as chronic obstructive pulmonary<br>
disease or asthma; allergenic conjunctivitis or rhinitis; hematologic neoplasm originated<br>
from immune cells, such as B-cell lymphoma, T-cell lymphoma, myeloid leukemia or the<br>
like; sepsis triggered by infection to gram-negative bacteria or coronavirus, severe acute<br>
respiratory syndrome, fulminant hepatitis or the like.<br>
[00144] Assay Example 13<br>
Test for Measuring Blood Level<br>
A pharmacokinetic study was performed using 6 week-old BDF1 male mice. The test<br>
substances were mixed with hydroxylpropylcellulose (low-molecular weight form)<br>
[HPC(L)] in 2.5-fold of the drug weight, and dissolved in dichloromethane. The<br>
solventwas evaporated to dryness. To make the dosing formation, the residue was<br>
suspended in distilled water to prepare the drug level of 20 mg/mL. The test compounds<br>
were administered compulsorily and orally at a dose of 200 mg/kg to the mice that had<br>
been starved for 16 hours. One hour after the administration, blood was collected from the<br>
orbits of two mice to obtain serum. Internal standards solution and 1 ml of distilled water<br>
were added to 100 L of serum thus obtained, and then extracted with diethylether. The<br>
solvent was evaporated under vacuum, and the residue was resolved with eluent to provide<br>
samples for the HPLC measurement. HPLC was performed by using reversed-phase type<br>
column, and acetonitrile-phosphate buffer (pH 2.5) was used as the eluent. Using<br>
regression curves (Y=aX+b) obtained from the standards, the drug levels in the sample<br>
serum were calculated. Their results are shown in Table 7 below.<br>
50<br>
[00145] [Table 7]<br><br><br>
As shown in the above test results, the compounds of the present invention having an<br>
acyl group at position 4 of the piperazine ring exhibited high blood levels quickly, one<br>
hour after the administration, as compared with the known control compounds 2, 3 and 9.<br>
[00146] Assay Example 14<br>
Proliferation Inhibitory Activity on Solid Tumor Cells<br>
Used in the test were MCF-7 cells which were established from human breast<br>
cancer and were cultured routinely under the conditions of 37C and 5% CO2, in MEM<br>
medium supplemented with 10 % fetal calf serum, 25 mM of HEPES and 0.1 mg/ml<br>
kanamycin. The MCF-7 cells in a logarithmic growth phase were treated with<br>
trypsin/EDTA to prepare single cell suspension adjusted to 4.0 x 104 cells/ml in MEM<br>
medium (supplemented with 10 % fetal calf serum, 25 mM of HEPES and 0.1 mg/ml<br>
kanamycin). Test compounds were dissolved in DMSO and diluted with RPMI 1640<br>
medium (supplemented with 10 % fetal calf serum, 25 mM of HEPES and 0.1 mg/ml<br>
kanamycin) to a concentration of 2.0 x 10-4 to 2.0 x 10-9M.<br>
The cell suspension was filled in a 96-wells microplate at a rate of 0.1 ml per well<br>
and was cultured for 24 hours so as to make the cells to adhere to the microplate. Then, it<br>
was added with 0.1 ml of the sample solution and cultured at 37C for 72 hours in 5% CO2.<br>
50 % Growth inhibition concentrations (GI50 M) were calculated from growth<br>
inhibitions at various sample concentrations. The results are as shown in Table 8.<br>
In the foregoing, when the cells other than MCF-7 are used, instead of adding 10 %<br>
fetal bovine serum, the following media were used, and the following single cell<br>
suspensions were prepared.<br>
PC-3 prostate cancer cells: 10% fetal bovine serum in F12K medium, single cell<br>
suspension of 2 x 104 cells;<br>
A549 lung cancer cells: 10% fetal bovine serum in DMEM medium, single cell suspension<br>
of 1.5 xl04 cells;<br>
WiDr colon cancer cells: 10% fetal bovine serum in MEM medium, single cell suspension<br>
of3xl04 cells;<br><br>
51<br>
B16F10 melanoma cells: 10% fetal bovine serum in RPMI 1640 medium, single cell<br>
suspension of 1 x 104 cells;<br><br>
Compound 25<br>
0.27	3.21	0.92	0.99	0.98<br>
Compound 27	0.31	4.63	1.32	1.12	1.14<br>
Compound 28	0.27	2.66	1.27	0.83	1.21<br>
Compound 29	0.32	3.93	2.58	1.32	0.70<br>
Compound 30	0.77	3.32	3.74	1.52	0.41<br>
Compound 31	0.32	1.51	1.43	0.65	0.05<br>
Compound 32	0.38	2.14	1.33	0.83	
Compound 33	0.51	2.91	1.46	1.05	
Compound 34	0.55	2.91	2.07	1.38	0.14<br>
Compound 35	0.73	2.84	2.10	1.22	0.10<br>
INDUSTRIAL APPLICABILITY<br>
[00148] The agents of the present invention can be used for the prevention or treatment of<br>
disorders of immune system involving in PI3K, such as autoimmune diseases, organ<br>
transplantation, allergic or inflammatory diseases, hematologic neoplasm, sepsis or the<br>
like. Furthermore, they can be used for the treatment of solid tumors. Moreover, they can<br>
be used as PI3K inhibitors for the treatment of a variety of disorders.<br>
52<br><br>
Claims<br>
1.	An immunosuppressive agent comprising as an effective ingredient a heterocyclic<br>
compound represented by Formula (I):<br><br>
wherein,<br>
X represents a nitrogen atom or CH;<br>
both or either of R1 and R2 represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difluoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
R6 represents a morpholino (optionally substituted with one or two C1-C6 alkyl groups), a<br>
pyrrolidinyl (optionally substituted with a hydroxy C1-C6 alkyl), a piperidino (which is<br>
optionally substituted with one or two oxygen atoms, a hydroxyl group, a formyl, or a C1-<br>
C6 alkyl), a piperazinyl (optionally substituted with one or two oxygen atoms, the nitrogen<br>
at position 4 being optionally substituted with a substituent selected from the group<br>
consisting of a formyl, a C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl,<br>
an aromatic carbonyl, a benzylcarbonyl, and a substituted carbamoyl), or a 1,4-diazepano<br>
(optionally substituted with one or two oxygen atoms, the nitrogen at position 4 being<br>
optionally substituted with a substituent selected from the group consisting of a formyl, a<br>
C1-C6 hydroxyalkyl, a C1-C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a<br>
benzylcarbonyl, a substituted carbamoyl);<br>
or a pharmaceutically acceptable salt thereof.<br>
2.	The immunosuppressive agent according to Claim 1, wherein either of R1 or R2 is a<br>
hydroxyl group.<br>
53<br><br>
3.	The immunosuppressive agent according to Claim 1 or 2, wherein either of R1 or<br>
R2 is a hydroxyl group, and R3 is a difluoromethyl.<br>
4.	The immunosuppressive agent according to Claim 1, wherein both of R1 and R2 are<br>
hydrogens, and R3 is a difluoromethyl.<br>
5.	The immunosuppressive agent according to any one of Claims 1 to 4, wherein R6 is<br>
a 4-acetylpiperazine.<br>
6.	The imminosuppressive agent according to Claim 1, wherein said heterocyclic<br>
compound is selected from the group consisting of:<br>
2-(2-methylbenzimidazol-1 -yl)-4,6-dimorpholino-1,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4,6-dimorpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-morpholino-6-(piperazin-l-yl)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(5 -oxo-1,4-diazepan-1 -yl)-1,3,5-<br>
triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(3 -oxopiperazin-1 -yl)-1,3,5 -<br>
triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-6-(4-formylpiperazin-1 -yl)-4-morpholino-1,3,5-<br>
triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-6-(3,5-dioxopiperazin-l-yl)-4-morpholino-l,3,5-<br>
triazine;<br>
2-(benzimidazol-l-yl)-4-(trans-2,3-dimethylmorpholino)-6-morpholino-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-morpholino-6-piperidino-l,3,5-triazine;<br>
2-(6-amino-2-difluoromethylbenzimidazol-l-yl)-4-(cis-2,3-dimethylmorpholino)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethyl-6-ethoxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine;<br>
2-(2-difluoromethyl-4-methylbenzimidazol-l-yl)-4,6-dimorpholino-l,3)5-triazine;<br>
2-(2-difluoromethyl-5-hydroxybenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine;<br>
2-(2-aminobenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine;<br>
2-(6-amino-2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholino-1,3,5-triazine;<br>
54<br><br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(2-hydroxymethylpyrrolidin-1 -yl)-6-<br>
morpholino-l,3,5-triazine;<br>
2-(2-methylbenzimidazol-1 -yl)-4,6-dimorpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-l-yl)-4,6-dimorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(piperazin-1 -yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(5 -oxo-1,4-diazepan-1 -<br>
yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-morpholino-6-(3-oxopiperazin-l-yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1-yl)-6-(4-formylpiperazin-1-yl)-4-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-(3,3-dimethylmorpholino)-6-<br>
morpholinopyrimidine;<br>
2-(2-aminobenzimidazol-1 -yl)-4,6-dimorpholinopyrimidine;<br>
2-(2-difluoromethyl-4-methoxybenzimidazol-l-yl)-4-(2,6-dimethylmorpholino)-6-<br>
morpholinopyrimidine; or<br>
2-(5-ammo-2-difluoromethylbenzimidazol-l-yl)-4,6-di(2,6-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(2-hydroxymethylpyrrolidin-1-yl)-6-<br>
morpholinopyrimidine;<br>
2-(6-amino-4-chrolo-2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(6-amino-4-chrolo-2-difluoromethylbenzimidazol-l-yl)-4-[methyl(l-methylpiperidin-4-<br>
yl)amino]-6-morpholino-l,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(2-hydroxymethylpyrrolidin-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(4-chrolo-2-difluoromethyl-5 -hydroxybenzimidazol-1 -yl)-4,6-dimorpholino-1,3,5-<br>
triazine;<br>
2-(5,6-dimethyl-2-difluoromethylbenzimidazol-l-yl)-4,6-dimorpholino-l,3,5-triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-morpholino-1,3,5-<br>
triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(cz.y-2,3 -<br>
dimethylmorpholino)-l,3,5-triazine;<br>
55<br><br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(trans-2,3-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(2,2-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-6-<br>
morpholino-1,3,5-triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-6-morpholino-<br>
1,3,5-triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-hydroxymethylbenzimidazol-1 -yl)-6-morpholino-1,3,5-<br>
triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(cis-2,3-<br>
dimethy lmorpholino)pyrimidine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetylpiperazin-l-yl)-2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-hydroxymethylbenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
morpholino-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
(cis-2,3-dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
(trans-2,3-dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
(2,2-dimethylmorpholino)-1,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-[4-(N,N-<br>
dimethylcarbamoylpiperazin)-1 -yl]-6-morpholino-1,3,5-triazine;<br>
56<br><br>
2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-<br>
l-yl]-6-morpholino-l,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
morpholino-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-1 -yl]-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
(cis-2,3-dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
(trans-2,3 -dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
(2,2-dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-[4-(N,N-<br>
dimethylcarbamoylpiperazin)-l-yl]-6-morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-<br>
1 -yl] -6-morpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-morpholino-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-(cw-2,3-<br>
dimethylmorpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(2-furoyl)piperazin-1 -yl] -6-(trans-2,3 -<br>
dimethylmorpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(2-furoyl)piperazin-1 -yl] -6-(2,2-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-[4-(2-furoyl)piperazin-1 -yl]-6-<br>
morpholino-1,3,5 -triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-<br>
morpholino-l,3,5-triazine;<br>
4- [4-(2-furoyl)piperazin-1 -yl] -2-(2-hydroxymethylbenzimidazol-1 -yl)-6-morpholino-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-<br>
morpholinopyrimidine;<br>
57<br><br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-(cis-2,3-<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-(trans-2,3-<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-<br>
morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-<br>
morpholinopyrimidine;<br>
4-[4-(2-furoyl)piperazin-1 -yl]-2-(2-hydroxymethylbenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-morpholino-1,3,5-<br>
triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(cis-2,3-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(2,2-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
4-(4-acetonylpiperazin-1-yl)-2-(2-difluoromethy-4-hydroxybenzimidazol-1-yl)-6-<br>
morpholino)-l ,3,5-triazine;<br>
4-(4-acetonylpiperazin-1-yl)-2-(4-amino-2-difluoromethylbenzimidazol-1-yl)-6-<br>
morpholino-1,3,5-triazine;<br>
4-(4-acetonylpiperazin-1-yl)-2-(2-hydroxymethylbenzimidazol-1-yl)-6-morpholino-1,3,5-<br>
triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(cis-2,3 -<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
58<br><br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-hydroxymethylbenzimidazol-l-yl)-6-<br>
morpholinopyrimidinne;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -yl)-1,3,5-<br>
triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(cis-2,3-dimethylmorpholino)-6-(4-<br>
propionylpiperazin-1 -yl)-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(trans-2,3-dimethylmorpholino)-6-(4-<br>
propionylpiperazin-1 -yl)-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-(4-<br>
propionylpiperazin-1 -yl)-1,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-morpholino-6-(4-propionylpiperazin-<br>
l-yl)-l,3,5-triazine;<br>
2-(4-aniino-2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)-l,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1-yl)-4-morpholino-6-(4-propionylpiperazin-1-yl)-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(cis-2,3-dimethylmorpholino-6-(4-<br>
propionylpiperazin-1 -yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(trans-2,3-dimethylmorpholino-6-(4-<br>
propionylpiperazin-1 -yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethylmorpholino-6-(4-<br>
propionylpiperazin-1 -yl)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-morpholino-6-(4-propionylpiperazin-<br>
l-yl)pyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)pyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)pyrimidine;<br>
59<br><br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazin-1 -yl)-6-morpholino-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxyacetylpiperazin-l-yl)-6-(cis-2,3-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxyacetylpiperazin-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazin-1 -yl)-6-(2,2-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazin-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazin-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-morpholino-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxyacetylpiperazi-l-yl)-6-(cis-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxyacetylpiperazi-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxyacetylpiperazi-l-yl)-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholino-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-(cis-2,3 -<br>
dimethylmorpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(3-hydroxypropyl)piperazi-l-yl]-6-(trans-2,3-<br>
dimethylmorpholino-1,3,5 -triazine;<br>
60<br><br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-(2,2-<br>
dimethylmorpholino-l,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -<br>
6-morpholino-l,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholino-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(3-hydroxypropyl)piperazi-l-yl]-6-(cis-2,3-<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-(trans-2,3-<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-(2,2-<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -<br>
6-morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-4-[4-(3-hydroxypropyl)piperazi-l-yl]-6-<br>
morpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-[4-(3-hydroxypropyl)piperazi-1 -yl]-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxycarbonylpiperazin-l-yl)-6-(cis-2,3-<br>
dimetylmorpholino)-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-(trans-<br>
2,3-dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1-yl)-4-(4-methoxycarbonylpiperazin-1-yl)-6-(2,2-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-<br>
6-morpholino-l,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxycarbonylpiperazin-l-yl)-6-<br>
morpholino-1,3,5-triazine;<br>
61<br><br>
2-(2-hydroxymethylbenzimidazol-1-yl)-4-(4-methoxycarbonylpiperazin-1-yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-(cis-2,3 -<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-(trans-<br>
2,3-dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxycarbonylpiperazin-l-yl)-6-(2,2-<br>
dimethy lmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(4-methoxycarbonylpiperazin-1-yl)-<br>
6-morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(5-oxo-1,4-diazepan-1 -yl)-1,3,5-<br>
triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(3 -oxopiperazin-1 -yl)-1,3,5 -<br>
triazine; and<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-6-(3,5-dioxopiperazin-1 -yl)-4-morpholino-1,3,5-<br>
triazine.<br>
7.	The immunosuppressive agent according to Claim 1, wherein the heterocyclic<br>
compound is selected from the group consisting of:<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(2-hydroxymethylpyrrolidin-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-<br>
morpholinopyrimidine; and<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(3,3 -dimethylmorpholino)-6-<br>
morpholinopyrimidine.<br>
8.	The immunosuppressive agent according to Claim 1, wherein the heterocyclic<br>
compound is selected from the group consisting of:<br>
62<br><br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4,6-dimorpholino-1,3,5-triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine; and<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-morpholino-1,3,5-<br>
triazine.<br>
9.	The immunosuppressive agent according to any one of Claims 1 to 8, wherein the<br>
disorder of interest is rejection or graft versus host disease; an inflammatory bowel disease<br>
such as ulcerative colitis or Crohn disease; an inflammatory or allergenic skin disease such<br>
as psoriasis or atopic dermatitis; an inflammatory or allergenic respiratory disorder such as<br>
obstructive pulmonary disease or asthma; autoimmune disease such as rheumatoid arthritis,<br>
systemic lupus erythematosus, scleroderma or Sjogren syndrome; malignant lymphoma,<br>
multiple myeloma, leukemia; sepsis, fulminant hepatitis or the like.<br>
10.	A heterocyclic compound represented by the general Formula (II):<br><br>
wherein,<br>
n represents 0-2;<br>
X represents a nitrogen atom or CH;<br>
Y represents -(CH2)n1-, wherein n1 is 1-2;<br>
R1 and R2, both or either, represent a hydrogen atom, a hydroxyl group, a halogen, an<br>
amino group, a C1-C6 alkylamino group, a C1-C6 alkoxy group, a C1-C6 alkyl group, or a<br>
cyano group;<br>
R3 represents a hydrogen atom, a difluoromethyl group, an amino group, a C1-C6<br>
alkylamino group, a methyl or a hydroxymethyl group;<br>
R4 and R5 represent a hydrogen atom, or a C1-C6 alkyl group;<br>
63<br><br>
R7 represents a hydrogen atom, a C1-C6 alkyl group, a formyl, a C1-C6 hydroxyalkyl, a C1-<br>
C6 alkoxycarbonyl, a C1-C6 oxoalkyl, an aromatic carbonyl, a benzylcarbonyl, or a<br>
substituted carbamoyl;<br>
or a pharmaceutically acceptable salt thereof.<br>
11. The compound according to Claim 10, wherein the heterocyclic compound is:<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-morpholino-1,3,5-<br>
triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(cis-2,3-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(2,2-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-6-<br>
morpholino-1,3,5-triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-6-morpholino-<br>
1,3,5-triazine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-hydroxymethylbenzimidazol-1 -yl)-6-morpholino-1,3,5-<br>
triazine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(cis-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetylpiperazin-1 -yl)-2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetylpiperazin-l-yl)-2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetylpiperazin-l-yl)-2-(2-hydroxymethylbenzimidazol-l-yl)-6-<br>
morpholinopyrimidine;<br>
64<br><br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
(cis-2,3-dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
(trans-2,3-dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
(2,2-dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4- [4-(N,N-<br>
dimethylcarbamoylpiperazin)-1 -yl] -6-morpholino-1,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-<br>
l-yl]-6-morpholino-l,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-1 -yl]-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
(cis-2,3-dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
(trans-2,3-dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-l-yl]-6-<br>
(2,2-dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-[4-(N,N-<br>
dimethylcarbamoylpiperazin)-l-yl]-6-morpholinopyrimidine;<br>
2-(4-arnino-2-difluoromethylbenzimidazol-l-yl)-4-[4-(N,N-dimethylcarbamoylpiperazin)-<br>
1 -yl] -6-morpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4- [4-(N,N-dimethylcarbamoylpiperazin)-1 -yl] -6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-[4-(2-furoyl)piperazin-1 -yl]-6-morpholino-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-(cis-2,3-<br>
dimethylmorpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-[4-(2-furoyl)piperazin-1 -yl]-6-(trans-2,3-<br>
dimethylmorpholino-l,3,5-triazine;<br>
65<br><br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-(2,2-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4- [4-(2-furoyl)piperazin-1 -yl] -6-<br>
morpholino-1,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4- [4-(2-furoyl)piperazin-1 -yl] -6-<br>
morpholino-1,3,5-triazine;<br>
4- [4-(2-furoyl)piperazin-1 -yl] -2-(2-hydroxymethylbenzimidazol-1 -yl)-6-morpholino-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(2-furoyl)piperazin-1 -yl] -6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-(cis-2,3-<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(2-furoyl)piperazin-1 -yl] -6-(trans-2,3 -<br>
dimethy lmorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-[4-(2-furoyl)piperazin-l-yl]-6-<br>
morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4- [4-(2-furoyl)piperazin-1 -yl] -6-<br>
morpholinopyrimidine;<br>
4-[4-(2-furoyl)piperazin-l-yl]-2-(2-hydroxymethylbenzimidazol-l-yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-morpholino-1,3,5 -<br>
triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(cis-2,3-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(2,2-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
66<br><br>
4-(4-acetonylpiperazin-1-yl)-2-(2-hydroxymethylbenzimidazol-1-yl)-6-morpholino-1,3,5-<br>
triazine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(cis-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetonylpiperazin-l-yl)-2-(2-difluoromethylbenzimidazol-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(2-difluoromethylbenzimidazol-1 -yl)-6-(2,2-<br>
dimethy lmorpholino)pyrimidine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-1 -yl)-2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-6-<br>
morpholinopyrimidine;<br>
4-(4-acetonylpiperazin-1-yl)-2-(2-hydroxymethylbenzimidazol-1-yl)-6-<br>
morpholinopyrimidinne;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -yl)-1,3,5-<br>
triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(cis-2,3 -dimethylmorpholino)-6-(4-<br>
propionylpiperazin-1 -yl)-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(trans-2,3 -dimethylmorpholino)-6-(4-<br>
propionylpiperazin-1 -yl)-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethylmorpholino)-6-(4-<br>
propionylpiperazin-1 -yl)-1,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-morpholino-6-(4-propionylpiperazin-<br>
l-yl)-l,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)-l,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -yl)-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(cis-2,3-dimethylmorpholino-6-(4-<br>
propionylpiperazin-1 -yl)pyrimidine;<br>
67<br><br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(trans-2,3 -dimethylmorpholino-6-(4-<br>
propionylpiperazin-1 -yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(2,2-dimethylmorpholino-6-(4-<br>
propionylpiperazin-1 -yl)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-l-yl)-4-morpholino-6-(4-propionylpiperazin-<br>
l-yl)pyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)pyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-morpholino-6-(4-propionylpiperazin-1 -<br>
yl)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxyacetylpiperazi-l-yl)-6-morpholino-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxyacetylpiperazi-l-yl)-6-(cis-2,3-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxyacetylpiperazi-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-(2,2-<br>
dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1-yl)-4-(4-methoxyacetylpiperazi-1-yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-morpholino-<br>
1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1-yl)-4-(4-methoxyacetylpiperazi-1-yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-(cis-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxyacetylpiperazi-l-yl)-6-(trans-2,3-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(4-methoxyacetylpiperazi-1 -yl)-6-<br>
morpholinopyrimidine;<br>
68<br><br>
2-(4-amino-2-difluoromethylbenzimidazol-1-yl)-4-(4-methoxyacetylpiperazi-1-yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1-yl)-4-(4-methoxyacetylpiperazi-1-yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-(cis-2,3 -<br>
dimethylmorpholino-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(3-hydroxypropyl)piperazi-l-yl]-6-(trans-2,3-<br>
dimethylmorpholino-1,3,5 -triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-[4-(3 -hydroxypropyl)piperazi-1 -yl] -6-(2,2-<br>
dimethylmorpholino-1,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -<br>
6-morpholino-l,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholino-1,3,5 -triazine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(3-hydroxypropyl)piperazi-l-yl]-6-(cis-2,3-<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-[4-(3 -hydroxypropyl)piperazi-1 -yl] -6-(trans-2,3 -<br>
dimethylmorpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-[4-(3-hydroxypropyl)piperazi-l-yl]-6-(2,2-<br>
dimethy lmorpholinopyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -<br>
6-morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4- [4-(3 -hydroxypropyl)piperazi-1 -yl] -6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholino-1,3,5 -triazine;<br>
69<br><br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-(cis-2,3 -<br>
dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-(trans-<br>
2,3-dimethylmorpholino)-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxycarbonylpiperazin-l-yl)-6-(2,2-<br>
dimethylmorpholino)-1,3,5-triazine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1-yl)-<br>
6-morpholino-l ,3,5-triazine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1-yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholino-1,3,5-triazine;<br>
2-(2-hydroxymethylbenzimidazol-1-yl)-4-(4-methoxycarbonylpiperazin-1-yl)-6-<br>
morpholino-l,3,5-triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-l-yl)-4-(4-methoxycarbonylpiperazin-l-yl)-6-(cis-2,3-<br>
dimethy lmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-(trans-<br>
2,3-dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-(2,2-<br>
dimethylmorpholino)pyrimidine;<br>
2-(2-difluoromethyl-4-hydroxybenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-<br>
6-morpholinopyrimidine;<br>
2-(4-amino-2-difluoromethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-hydroxymethylbenzimidazol-1 -yl)-4-(4-methoxycarbonylpiperazin-1 -yl)-6-<br>
morpholinopyrimidine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(5-oxo-1,4-diazepan-1-yl)-1,3,5-<br>
triazine;<br>
2-(2-difluoromethylbenzimidazol-1 -yl)-4-morpholino-6-(3 -oxopiperazin-1 -yl)-1,3,5-<br>
triazine; and<br>
2-(2-difluoromethylbenzimidazol-l-yl)-6-(3,5-dioxopiperazin-l-yl)-4-morpholino-l,3,5-<br>
triazine.<br>
70<br><br>
12. An antitumor agent comprising as an effective ingredient a compound according to<br>
either of Claims 10 or 11.<br>
71<br><br>
A novel immunosuppressive agent, more specifically an immunosuppressive agent<br>
comprising, as an active ingredient, a heterocyclic compound represented by the general<br>
formula (I) (wherein X or other variables are as defined in the specification) or a<br>
pharmaceutically acceptable salt thereof; a novel heterocyclic compound represented by<br>
the general formula (II) (wherein X or other variables are as defined in the specification)<br>
or a pharmaceutically acceptable salt thereof; and use of the compound or salt as an<br>
antitumor agent.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1hYnN0cmFjdC5wZGY=" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1jbGFpbXMucGRm" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1jb3JyZXNwb25kZW5jZSBvdGhlcnMucGRm" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-correspondence others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1kZXNjcmlwdGlvbiBjb21wbGV0ZS5wZGY=" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-description complete.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1kcmF3aW5ncy5wZGY=" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-drawings.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1mb3JtIDEucGRm" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-form 1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1mb3JtIDMucGRm" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-form 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1mb3JtIDUucGRm" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-form 5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHB1YmxpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-international publication.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1pbnRlcm5hdGlvbmFsIHNlYXJjaCByZXBvcnQucGRm" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-international search report.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1vdGhlcnMgcGN0IGZvcm0ucGRm" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-others pct form.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1wY3QgcHJpb3JpdHkgZG9jdW1lbnQgbm90aWZpY2F0aW9uLnBkZg==" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-pct priority document notification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MDMyMjAta29sbnAtMjAwNy1wcmlvcml0eSBkb2N1bWVudC5wZGY=" target="_blank" style="word-wrap:break-word;">03220-kolnp-2007-priority document.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgwMi0wOC0yMDEzKS1BTk5FWFVSRSBUTyBGT1JNIDMucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(02-08-2013)-ANNEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgwMi0wOC0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(02-08-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgwMy0wOS0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(03-09-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgwMy0wOS0yMDEzKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(03-09-2013)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxMy0xMi0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(13-12-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNC0xMi0yMDEyKS1BQlNUUkFDVC5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(14-12-2012)-ABSTRACT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNC0xMi0yMDEyKS1DTEFJTVMucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(14-12-2012)-CLAIMS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNC0xMi0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(14-12-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNC0xMi0yMDEyKS1ERVNDUklQVElPTiAoQ09NUExFVEUpLnBkZg==" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(14-12-2012)-DESCRIPTION (COMPLETE).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNC0xMi0yMDEyKS1EUkFXSU5HUy5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(14-12-2012)-DRAWINGS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNC0xMi0yMDEyKS1GT1JNLTEucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(14-12-2012)-FORM-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNC0xMi0yMDEyKS1GT1JNLTEzLnBkZg==" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(14-12-2012)-FORM-13.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNC0xMi0yMDEyKS1GT1JNLTIucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(14-12-2012)-FORM-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNC0xMi0yMDEyKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(14-12-2012)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNC0xMi0yMDEyKS1QQS5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(14-12-2012)-PA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNC0xMi0yMDEyKS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(14-12-2012)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNy0wMS0yMDEzKS1BTk5FWFVSRSBUTyBGT1JNIDMucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(17-01-2013)-ANNEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxNy0wMS0yMDEzKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(17-01-2013)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxOS0xMi0yMDEyKS1DT1JSRVNQT05ERU5DRS5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(19-12-2012)-CORRESPONDENCE.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxOS0xMi0yMDEyKS1FTkdMSVNIIFRSQU5TTEFUSU9OIE9GIFBSSU9SSVRZIERPQ1VNRU5ULnBkZg==" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(19-12-2012)-ENGLISH TRANSLATION OF PRIORITY DOCUMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgxOS0xMi0yMDEyKS1QRVRJVElPTiBVTkRFUiBSVUxFIDEzNy5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(19-12-2012)-PETITION UNDER RULE 137.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgzMS0wNy0yMDEyKS1BTk5FWFVSRSBUTyBGT1JNIDMucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(31-07-2012)-ANNEXURE TO FORM 3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgzMS0wNy0yMDEyKS1FWEFNSU5BVElPTiBSRVBPUlQgUkVQTFkgUkVDSUVWRUQucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(31-07-2012)-EXAMINATION REPORT REPLY RECIEVED.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgzMS0wNy0yMDEyKS1PVEhFUlMtMS5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(31-07-2012)-OTHERS-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgzMS0wNy0yMDEyKS1PVEhFUlMtMi5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(31-07-2012)-OTHERS-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgzMS0wNy0yMDEyKS1PVEhFUlMtNC5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(31-07-2012)-OTHERS-4.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgzMS0wNy0yMDEyKS1PVEhFUlMtNS5wZGY=" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(31-07-2012)-OTHERS-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LSgzMS0wNy0yMDEyKS1PVEhFUlMucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-(31-07-2012)-OTHERS.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LUFTU0lHTk1FTlQucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-ASSIGNMENT.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LUNPUlJFU1BPTkRFTkNFIE9USEVSUy0xLjEucGRm" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-CORRESPONDENCE OTHERS-1.1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1rb2xucC0yMDA3LWZvcm0gMTgucGRm" target="_blank" style="word-wrap:break-word;">3220-kolnp-2007-form 18.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MzIyMC1LT0xOUC0yMDA3LVBBLnBkZg==" target="_blank" style="word-wrap:break-word;">3220-KOLNP-2007-PA.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QtMDMyMjAta29sbnAtMjAwNy5qcGc=" target="_blank" style="word-wrap:break-word;">abstract-03220-kolnp-2007.jpg</a></p>
		<br>
		<div class="pull-left">
			<a href="264537-method-and-device-for-measuring-circulation-quantity-of-bed-material-in-circulating-fluidized-bed-combustor.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="264539-an-improved-repeater-antenna-for-use-in-point-to-point-applications.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>264538</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>3220/KOLNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>02/2015</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>09-Jan-2015</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>05-Jan-2015</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>31-Aug-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>ZENYAKU KOGYO KABUSHIKIKAISHA</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>2-9, NIHONBASHI-MUROMACHI 3-CHOME, CHUO-KU, TOKYO</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>HARUTA KAZUHIKO</td>
											<td>C/O LABORATORY OF ZENYAKU KOGYO KABUSHIKIKAISHA, 33-7, OHIZUMI-MACHI 2-CHOME,, NERIMA-KU, TOKYO 1780062</td>
										</tr>
										<tr>
											<td>2</td>
											<td>MATSUNO TOSHIYUKI</td>
											<td>C/O LABORATORY OF ZENYAKU KOGYO KABUSHIKIKAISHA, 33-7, OHIZUMI-MACHI 2-CHOME,, NERIMA-KU, TOKYO 1780062</td>
										</tr>
										<tr>
											<td>3</td>
											<td>TSUCHIDA YOSHIO</td>
											<td>C/O LABORATORY OF ZENYAKU KOGYO KABUSHIKIKAISHA, 33-7, OHIZUMI-MACHI 2-CHOME,, NERIMA-KU, TOKYO 1780062</td>
										</tr>
										<tr>
											<td>4</td>
											<td>WATANABE TETSUO</td>
											<td>C/O LABORATORY OF ZENYAKU KOGYO KABUSHIKIKAISHA, 33-7, OHIZUMI-MACHI 2-CHOME,, NERIMA-KU, TOKYO 1780062</td>
										</tr>
										<tr>
											<td>5</td>
											<td>YOSHIOKA KIMITOMO</td>
											<td>C/O LABORATORY OF ZENYAKU KOGYO KABUSHIKIKAISHA, 33-7, OHIZUMI-MACHI 2-CHOME,, NERIMA-KU, TOKYO 1780062</td>
										</tr>
										<tr>
											<td>6</td>
											<td>YUI RYUGO</td>
											<td>C/O LABORATORY OF ZENYAKU KOGYO KABUSHIKIKAISHA, 33-7, OHIZUMI-MACHI 2-CHOME,, NERIMA-KU, TOKYO 1780062</td>
										</tr>
										<tr>
											<td>7</td>
											<td>YAGUCHI SHINICHI</td>
											<td>C/O LABORATORY OF ZENYAKU KOGYO KABUSHIKIKAISHA, 33-7, OHIZUMI-MACHI 2-CHOME,, NERIMA-KU, TOKYO 1780062</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>A61K 31/5377</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/JP2006/304937</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2006-03-13</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>2005-069255</td>
									<td>2005-03-11</td>
								    <td>Japan</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/264538-immunosuppressive-agent-and-anti-tumor-agent-comprising-heterocyclic-compound-as-active-ingredient by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 01:50:52 GMT -->
</html>
